WO1994029452A2 - Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease - Google Patents

Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease Download PDF

Info

Publication number
WO1994029452A2
WO1994029452A2 PCT/US1994/006331 US9406331W WO9429452A2 WO 1994029452 A2 WO1994029452 A2 WO 1994029452A2 US 9406331 W US9406331 W US 9406331W WO 9429452 A2 WO9429452 A2 WO 9429452A2
Authority
WO
WIPO (PCT)
Prior art keywords
ribozyme
seq
rna molecule
rna
enzymatic rna
Prior art date
Application number
PCT/US1994/006331
Other languages
French (fr)
Other versions
WO1994029452A3 (en
Inventor
Kenneth G. Draper
Original Assignee
Ribozyme Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribozyme Pharmaceuticals, Inc. filed Critical Ribozyme Pharmaceuticals, Inc.
Priority to AU70538/94A priority Critical patent/AU7053894A/en
Publication of WO1994029452A2 publication Critical patent/WO1994029452A2/en
Publication of WO1994029452A3 publication Critical patent/WO1994029452A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Definitions

  • This invention relates to methods for inhibition of fibrous and connective tissue disease, in particular the inhibition of genetic expression which leads to the reduction or elimination of unwanted fibrous or connective tissue during wound healing, tissue remodeling or the growth of fibromatous tissues.
  • Transforming growth factor ⁇ is perhaps the most ubiquitous and pleiotropic member of the cellular repertoire of cytokines which are involved in the regulation of cell growth. At least five isoforms of TGF j ⁇ are reported and a number of these exhibit tissue specific or differentiation specific expresssion.
  • the invention features use of ribozymes to treat or prevent fibrous and connective tissue disease, e.g. , by inhibiting the synthesis of transforming growth factor beta (TGF-/3) .
  • TGF-/3 transforming growth factor beta
  • Cleavage of targeted mRNAs (transforming growth factor beta mRNAs) expressed in keratinocytes, T- lymphocytes, monocytes, macrophages or muscle cells inhibits the synthesis of transforming growth factor ⁇ .
  • poten ⁇ tial targets noted above are also suitable for treatment with ribozymes, which will reduce the risk or occurrence of connective and fibrous tissue disease, such as epi ⁇ dermal growth factor (EGF) , inhibins, activins, transforming growth factor alpha (TGF-cx) , amphiregulin
  • EGF epi ⁇ dermal growth factor
  • TGF-cx transforming growth factor alpha
  • AR bone morphogenic proteins
  • BMPs bone morphogenic proteins
  • aFGF fibroblast growth factors
  • bFGF fibroblast growth factors
  • Ribozymes are RNA molecules having an enzymatic activity which is able to repeatedly cleave other separate organs.
  • RNA molecules in a nucleotide base sequence specific manner can be targeted to virtually any RNA transcript and efficient cleavage has been achieved in vi tro .
  • Kim et al . 84 Proc. Natl. Acad. of Sci. USA 8788, 1987; Haseloff and Gerlach, 334 Nature 585, 1988; Cech, 260 JAMA 3030, 1988; and Jefferies et al. , 17 Nucleic Acids Research 1371, 1989.
  • Ribozymes act by first binding to a target RNA. Such binding occurs through the target RNA binding portion of a ribozyme which is held in close proximity to an enzym ⁇ atic portion of the RNA which acts to cleave the target RNA. Thus, the ribozyme first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After a ribozyme has bound and cleaved its RNA target it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.
  • ribozyme The enzymatic nature of a ribozyme is advantageous over other technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its translation) since the effective concentration of ribozyme necessary to effect a thera ⁇ Commissionic treatment is lower than that of an antisense oligonucleotide.
  • This advantage reflects the ability of the ribozyme to act enzymatically.
  • a single ribozyme molecule is able to cleave many molecules of target RNA.
  • the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity is defined as the ratio of the rate of cleavage of the targeted RNA over the rate of cleavage of non-targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base pairing. Thus, it is thought that the specificity of action of a ribozyme is greater than that of antisense oligonucleotide binding the same RNA site.
  • This class of chemicals exhibits a high degree of specificity for cleavage of the intended target mRNA. Consequently, the ribozyme agent will only affect cells expressing that particular gene, and will not be toxic to normal tissues.
  • the invention can be used to treat or prevent (prophylactically) fibrous or connective tissue diseases.
  • the preferred administration protocol is in vivo administration to reduce the level of TGF-/3 activity.
  • the invention features an enzymatic RNA molecule (or ribozyme) which cleaves mRNA associated with development or maintenance of a fibrotic or fibromatous condition, e.g. , mRNA encoding TGF-j ⁇ l, - ⁇ 2 , or ⁇ 3 and in particular, those mRNA targets disclosed in Table 1.
  • mRNA associated with such diseases are readily identified by standard procedures known in the art . For example, genetic mutations which reduce occurence of such diseases indicate a useful target for ribozyme attack.
  • enzymatic RNA molecule an RNA molecule which has complementarity in a substrate binding region to a specified mRNA target, and also has an enzymatic activity which is active to specifically cleave that mRNA. That is, the enzymatic RNA molecule is able to intermolecularly cleave mRNA and thereby inactivate a target mRNA molecule. This complementarity functions to allow sufficient hybridization of the enzymatic RNA molecule to the target RNA to allow the cleavage to occur. One hundred percent complementarity is preferred, but complementarity as low as 50-75% may also be useful in this invention. For in vivo treatment, complementarity between 30 and 45 bases is preferred.
  • the enzymatic RNA molecule is formed in a hammerhead motif, but may also be formed in the motif of a hairpin, hepatitis delta virus, group I intron or RNaseP-like RNA (in association with an RNA guide sequence) .
  • hammerhead motifs are described by Rossi et al. , 8 Aids Research and Human Retroviruses 183, 1992, of hairpin motifs by Hampel et al., "RNA Catalyst for Cleaving Specific RNA Sequences", filed September 20, 1989, which is a continuation-in-part of U.S. Serial No.
  • RNA molecules of this invention has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule.
  • the invention features a mammalian cell which includes an enzymatic RNA molecule as described above.
  • the mammalian cell is a human cell.
  • the invention features an expression vector which includes nucleic acid encoding an enzymatic RNA molecule described above, located in the vector, e.g. , in a manner which allows expression of that enzymatic RNA molecule within a mammalian cell .
  • the invention features a method for treatment of a fibrotic or fibromatous condition by administering to a patient an enzymatic RNA molecule as described above.
  • the invention provides a class of chemical cleaving agents which exhibit a high degree of specificity for the mRNA causative of a psoriatic condition.
  • Such enzymatic RNA molecules can be delivered exogenously or endogenously to infected cells.
  • the small size (less than 40 nucleotides, preferably between 32 and 36 nucleotides in length) of the molecule allows the cost of treatment to be reduced.
  • ribozyme delivered for any type of treatment reported to date is an in vi tro transcript having a length of 142 nucleotides. Synthesis of ribozymes greater than 100 nucleotides in length is very difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. Delivery of ribozymes by expression vectors is primarily feasible using only ex vivo treatments. This limits the utility of this approach.
  • an alternative approach uses smaller ribozyme motifs (e.g. , of the hammerhead structure, shown generally in Fig. 1) and exogenous delivery. The simple structure of these molecules also increases the ability of the ribozyme to invade targeted regions of the mRNA structure.
  • the enzymatic RNA molecules of this invention can be used to treat fibromatous conditions or fibrous and connective tissue disorders. Such treatment can also be extended to other related genes in nonhuman primates. Affected animals can be treated at the time of fibrotic risk detection, or in a prophylactic manner. This timing of treatment will reduce the chance of further fibrous or connective tissue damage.
  • Ribozymes of this invention may be used as diagnostic tools to examine genetic drift and mutations within diseased cells.
  • the close relationship between ribozyme activity and the structure of the target RNA allows the detection of mutations in any region of the molecule which alters the base-pairing and three-dimensional structure of the target RNA.
  • multiple ribozymes described in this invention one may map nucleotide changes which are important to RNA structure and function in vi tro, as well as in cells and tissues.
  • Cleavage of* target RNAs with ribozymes may be used to inhibit gene expression and define the role (essentially) of specified gene products in the progression of disease. In this manner, other genetic targets may be defined as important mediators of the disease.
  • Drawing Fig. 1 is a diagrammatic representation of a hammer ⁇ head motif ribozyme showing stems I, II and III (marked (I) , (II) and (III) respectively) interacting with a target region. The 5' and 3' ends of both ribozyme and target are shown. Dashes indicate base-paired nucleotides.
  • Target Sites
  • Ribozymes targeting selected regions of mRNA associa ⁇ ted with fibrous or connective tissue disease are chosen to cleave the target RNA in a manner which preferably inhibits translation of the RNA. Genes are selected such that inhibition of translation will preferably inhibit cell replication, e.g. , by inhibiting production of a necessary protein. Selection of effective target sites within these critical regions of mRNA entails testing the accessibility of the target RNA to hybridization with various oligonucleotide probes. These studies can be performed using RNA probes and assaying accessibility by cleaving the hybrid molecule with RNaseH (see below) .
  • ribozyme probes designed from secondary structure predictions of the mRNAs, and assaying cleavage products by polyacrylamide gel electrophoresis (PAGE) , to detect the presence of cleaved and uncleaved molecules.
  • PAGE polyacrylamide gel electrophoresis
  • the method involves identifying potential cleavage sites for a hammerhead ribozyme, and then testing each of these sites to deter ⁇ mine their suitability as targets by ensuring that secondary structure formation is minimal.
  • the mRNA sequences are compared in an appropriate target region. Putative ribozyme cleavage sites are found. These sites represent the preferable sites for hammerhead ribozyme cleavage within these target mRNAs.
  • Short RNA substrates corresponding to each of the mRNA sites are designed. Each substrate is composed of two to three nucleotides at the 5' and 3' ends that will not base pair with a corresponding ribozyme recognition region. The unpaired regions flanked a central region of 12-14 nucleotides to which complementary arms in the ribozyme are designed.
  • the structure of each substrate sequence is predicted using a PC fold computer program. Sequences which give a positive free energy of binding are accepted. Sequences which give a negative free energy are modified by trimming one or two bases from each of the ends. If the modified sequences are still predicted to have a strong secondary structure, they are rejected.
  • ribozymes are designed to each of the RNA substrates. Ribozyme folding is also analyzed using PC fold.
  • Ribozyme molecules are sought which form hammerhead motif stem II (see Fig. 1) regions and contain flanking arms which are devoid of intramolecular base pairing. Often the ribozymes are modified by trimming a base from the ends of the ribozyme, or by introducing additional base pairs in stem II to achieve the desired fold. Ribozymes with incorrect folding are rejected. After substrate/ribozyme pairs are found to contain correct intramolecular structures, the molecules are folded together to predict intermolecular interactions. A schematic representation of a ribozyme with its coordinate base pairing to its cognate target sequence is shown in Fig. 1.
  • ribonuclease H assay provides a quick test of the use of the target site without requiring synthesis of a ribozyme. It can be used to screen for sites most suited for ribozyme attack.
  • Ribozymes useful in this invention can be produced by gene transcription as described by Cech, supra, ox by chemical synthesis. Chemical synthesis of RNA is similar to that for DNA synthesis. The additional 2' -OH group in RNA, however, requires a different protecting group strategy to deal with selective 3' -5' internucleotide bond formation, and with RNA susceptibility to degradation in the presence of bases. The recently developed method of RNA synthesis utilizing the t-butyldimethylsilyl group for the protection of the 2' hydroxyl is the most reliable method for synthesis of ribozymes.
  • the method reproduc- ibly yields RNA with the correct 3 '-5' internucleotide linkages, with average coupling yields in excess of 99%, and requires only a two-step deprotection of the polymer.
  • a method, based upon H-phosphonate chemistry of phosphoroamidites gives a relatively lower coupling efficiency than a method based upon phosphoroamidite chemistry. This is a problem for synthesis of DNA as well .
  • a promising approach to scale-up of automatic oligonucleotide synthesis has been described recently for the H-phosphonates.
  • a combination of a proper coupling time and additional capping of "failure" sequences gave high yields in the synthesis of oligodeoxynucleotides in scales in the range of 14 ⁇ moles with as little as 2 equivalents of a monomer in the coupling step.
  • Another alternative approach is to use soluble polymeric supports (e.g. , polyethylene glycols) , instead of the conventional solid supports. This method can yield short oligonucleo- tides in hundred milligram quantities per batch utilizing about 3 equivalents of a monomer in a coupling step.
  • soluble polymeric supports e.g. , polyethylene glycols
  • This method can yield short oligonucleo- tides in hundred milligram quantities per batch utilizing about 3 equivalents of a monomer in a coupling step.
  • Various modifications to ribozyme structure can be made to enhance the utility of ribozymes.
  • Such modifica ⁇ tions will enhance shelf-life, half-life in vi tro, stability, and ease of introduction of such ribozymes to the target site, e.g. , to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells.
  • Exogenous delivery of ribozymes benefits from chemical modification of the backbone, e.g., by the overall negative charge of the ribozyme molecule being reduced to facilitate diffusion across the cell membrane.
  • the present strategies for reducing the oligonucleotide charge include: modification of internucleotide linkages by methylphosphonates, use of phosphoramidites, linking oligonucleotides to positively charged molecules, and creating complex packages composed of oligonucleotides, lipids and specific receptors or effectors for targeted cells. Examples of such modifications include sulfur- containing ribozymes containing phosphorothioates and phosphorodithioates as internucleotide linkages in RNA.
  • Ribozymes may also contain ribose modified ribonucleotides.
  • Pyrimidine analogues are prepared from uridine using a procedure employing diethyl- amino sulphur trifluoride (DAST) as a starting reagent.
  • Ribozymes can also be either electrostatically or covalently attached to polymeric cations for the purpose of reducing charge.
  • the polymer can be attached to the ribozyme by simply converting the 3'-end to a ribonucleo- side dialdehyde which is obtained by a periodate cleavage of the terminal 2',3'-cis diol system.
  • other possible modifications may include different linker arms containing carboxyl, amino or thiol functionalities.
  • Yet further examples include use of methylphosphonates and 2'-0- methylribose and 5' or 3' capping or blocking with m 7 GpppG or m 3 2 ' 2 ' GpppG.
  • a kinased ribozyme is contacted with guanosine triphosphate and guanyltransferase to add an m 3 G cap to the ribozyme.
  • the ribozyme can be gel purified using standard procedure. To ensure that the ribozyme has the desired activity, it may be tested with and without the 5' cap using standard procedures to assay both its enzymatic activity and its stability.
  • Synthetic ribozymes including those containing various modifiers, can be purified by high pressure liquid chromatography (HPLC) .
  • HPLC high pressure liquid chromatography
  • Other liquid chromatography techniques, employing reverse phase columns and anion exchangers on silica and polymeric supports may also be used.
  • the only exception is that the coupling step is increased from 10 to 12 minutes.
  • the phosphoramidite concentration is 0.1 M.
  • Synthesis is done on a 1 ⁇ mole scale using a 1 ⁇ mole RNA reaction column (Glen Research) .
  • the average coupling efficiencies are between 97% and 98% for the 394 model, and between 97% and 99% for the 380B model, as determined by a calorimetric measurement of the released trityl cation.
  • the residue is suspended in 1 M tetra-n- butylammonium fluoride in dry THF (TBAF) , using a 20 fold excess of the reagent for every silyl group, for 16 hours at ambient temperature (about 15-25°C) .
  • THF dry THF
  • the reaction is quenched by adding an equal volume of sterile 1 M triethylamine acetate, pH 6.5.
  • the sample is cooled and concentrated on a SpeedVac to half the initial volume.
  • the ribozymes are purified in two steps by HPLC on a C4 300 A 5 mm DeltaPak column in an acetonitrile gradient.
  • the first step is a separation of 5' -DMT-protected ribozyme (s) from failure sequences lacking a 5' -DMT group.
  • Solvents used for this step are: A (0.1 M triethylammonium acetate, pH 6.8) and B (aceto- nitrile) .
  • the elution profile is: 20% B for 10 minutes, followed by a linear gradient of 20% B to 50% B over 50 minutes, 50% B for 10 minutes, a linear gradient of 50% B to 100% B over 10 minutes, and a linear gradient of 100% B to 0% B over 10 minutes.
  • the second step is a purification of a completely deblocked ribozyme by a treatment of 2% trifluoroacetic acid on a C4 300 A 5 mm DeltaPak column in an acetonitrile gradient.
  • Solvents used for this second step are: A (0.1 M Triethylammonium acetate, pH 6.8) and B (80% aceto- nitrile, 0.1 M triethylammonium acetate, pH 6.8) .
  • the elution profile is: 5% B for 5 minutes, a linear gradient of 5% B to 15% B over 60 minutes, 15% B for 10 minutes, and a linear gradient of 15% B to 0% B over 10 minutes.
  • the fraction containing ribozyme is cooled and lyophilized on a SpeedVac. Solid residue is dissolved in a minimum amount of ethanol and sodium perchlorate in acetone. The ribozyme is collected by centrifugation, washed three times with acetone, and lyophilized.
  • ribozymes While synthetic ribozymes are preferred in this invention, those produced by expression vectors can also be used. (See, McSwiggen, U.S. Serial No. 07/884,431, filed May 14, 1992, hereby incorporated by reference herein.) In designing a suitable ribozyme expression vector the following factors are important to consider. The final ribozyme must be kept as small as possible to minimize unwanted secondary structure within the ribozyme.
  • a promoter e.g. , the human cytomegalovirus immediate early promoter or human beta actin promoter
  • Such a promoter should express the ribozyme at a level suitable to effect production of enough ribozyme to destroy a target RNA, but not at too high a level to prevent other cellular activities from occurring (unless cell death itself is desired) .
  • a hairpin at the 5' end of the ribozyme is useful to protect the ribozyme from 5'-3' exonucleases.
  • a selected hairpin at the 3' end of the ribozyme gene is useful since it protects the ribozyme from 3' -5' exonuclease activity.
  • One example of a known hairpin is that present on the T7 RNA poly erase system. This signal is about 30 nucleo ⁇ tides in length. Other 3' hairpins of shorter length can be used to provide good RNA stability.
  • Such hairpins can be inserted within the vector sequences to allow standard ribozymes to be placed in an appropriate orientation and expressed with such sequences attached.
  • Poly(A) tails are also useful to protect the 3' end of the ribozyme. These can be provided by either includ- ing a poly(A) signal site in the expression vector (to signal a cell to add the poly(A) tail in vivo) , or by introducing a poly(A) sequence directly into the expres ⁇ sion vector. In the first approach the signal must be located to prevent unwanted secondary structure formation with other parts of the ribozyme. In the second approach, the poly(A) stretch may reduce in size over time when expressed in vivo, and thus the vector may need to be checked over time. Care must be taken in addition of a poly(A) tail which binds poly(A) binding proteins which prevent the ribozyme from acting.
  • Crude synthetic ribozyme (typically 350 ⁇ g at a time) is purified by separation on a 15% denaturing polyacryl- amide gel (0.75 mm thick, 40 cm long) and visualized by UV shadowing. Once excised, gel slices containing full length ribozyme are soaked in 5 ml gel elution buffer (0.5 M NH 4 OAc, 1 mM EDTA) overnight with shaking at 4°C. The eluent is desalted over a C-18 matrix (Sep-Pak cartridges, Millipore, Milford, MA) and vacuum dried.
  • 5 ml gel elution buffer 0.5 M NH 4 OAc, 1 mM EDTA
  • RNA is resuspended in 50-100 ⁇ l TE (TRIS 10 mM, EDTA 1 mM, pH 7.2) .
  • An aliquot of this solution is diluted 100 fold into 1 ml TE, half of which is used to spectrophotometric- ally quantitate the ribozyme solution.
  • the concentration of this dilute stock is typically 150-800 nM. Purity of the ribozyme is confirmed by the presence of a single band on a denaturing polyacrylamide gel.
  • a ribozyme may advantageously be synthesized in two or more portions.
  • Each portion of a ribozyme will generally have only limited or no enzymatic activity, and the activity will increase substantially (by at least 5-10 fold) when all portions are ligated (or otherwise juxta ⁇ posed) together.
  • a specific example of hammerhead ribozyme synthesis is provided below.
  • the method involves synthesis of two (or more) shorter "half" ribozymes and ligation of them together using T4 RNA ligase.
  • T4 RNA ligase For example, to make a 34 mer ribozyme, two 17 mers are synthesized, one is phosphoryl- ated, and both are gel purified. These purified 17 mers are then annealed to a DNA splint strand complementary to the two 17 mers. (Such a splint is not always necessary.) This DNA splint has a sequence designed to locate the two 17 mer portions with one end of each adjacent each other. The juxtaposed RNA molecules are then treated with T4 RNA ligase in the presence of ATP. The 34 mer RNA so formed is then HPLC purified. Preparation of Substrates
  • a substrate solution is made IX in assay buffer (75 mM Tris-HCl, pH 7.6; 0.1 mM EDTA, 10 mM MgCl 2 ) such that the concentration of substrate is less than 1 nM.
  • a ribozyme solution typically 20 nM is made IX in assay buffer and four dilutions are made using IX assay buffer. Fifteen ⁇ l of each ribozyme dilution (i.e. , 20, 16, 12, 8 and 4 nM) is placed in a separate tube. These tubes and the substrate tube are pre-incubated at 37°C for at least five minutes.
  • the reaction is started by mixing 15 ⁇ l of substrate into each ribozyme tube by rapid pipetting (note that final ribozyme concentrations are 10, 8, 6, 4, 2 nM) .
  • Five ⁇ l aliquots are removed at 15 or 30 second intervals and quenched with 5 ⁇ l stop solution (95% formamide, 20 mM EDTA xylene cyanol, and bromphenol blue dyes) .
  • 5 ⁇ l stop solution 95% formamide, 20 mM EDTA xylene cyanol, and bromphenol blue dyes
  • the samples are separated on either 15% or 20% polyacrylamide gels. Each gel is visualized and quantitated with an Ambis beta scanner (Ambis Systems, San Diego, CA) .
  • RNA substrate excess For the most active ribozymes, kinetic analyses are performed in substrate excess to determine K-, and K cat values.
  • the substrates For kinetic reactions with long RNA substrates (greater than 15 bases in length) the substrates are prepared by transcription using T7 RNA polymerase and defined templates containing a T7 promoter, and DNA encoding appropriate nucleotides of the target RNA.
  • the substrate solution is made IX in assay buffer (75 mM Tris- HCI, pH 7.6; 0.1 mM EDTA; 10 mM MgCl 2 ) and contains 58 nanomolar concentration of the long RNA molecules.
  • the reaction is started by addition of gel purified ribozymes to 1 ⁇ M concentration.
  • a simple reaction mechanism for ribozyme-mediated cleavage is: k- L k 2
  • the rate of the reaction is the rate of disappearance of substrate with time :
  • Such ribozymes can be selected and tested in in vivo or ex vivo systems.
  • Lipid molecules are dissolved in a volatile organic solvent (CHC1 3 , methanol, diethylether, ethanol, etc.) .
  • the organic solvent is removed by evaporation.
  • the lipid is hydrated into suspension with 0.Ix phosphate buffered saline (PBS) , then freeze-thawed 3x using liquid nitrogen and incubation at room temperature.
  • the suspension is extruded sequentially through a 0.4 ⁇ m, 0.2 ⁇ m and 0.1 ⁇ m polycarbonate filters at maximum pressure of 800 psi.
  • the ribozyme is mixed with the extruded liposome suspension and lyophilized to dryness.
  • the lipid/ribozyme powder is rehydrated with water to one-tenth the original volume.
  • the suspension is diluted to the minimum volume required for extrusion (0.4 ml for 1.5 ml barrel and 1.5 ml for 10 ml barrel) with IxPBS and re-extruded through 0.4 ⁇ m, 0.2 ⁇ m, 0.1 ⁇ m polycarbonate filters.
  • the liposome entrapped ribozyme is separated from untrapped ribozyme by gel filtration chromatography (SEPHAROSE CL-4B, BIOGEL A5M) .
  • the liposome extractions are pooled and sterilized by filtration through a 0.2 ⁇ m filter.
  • the free ribozyme is pooled and recovered by ethanol precipitation.
  • the liposome concentration is determined by incorporation of a radioactive lipid.
  • ribozyme concentration is determined by labeling with 32 P. Rossi et al. , 1992, supra (and references cited therein) describe other methods suitable for preparation of liposomes. Examples of other useful liposome preparations which display similar degrees of uptake of both a radioactive lipid marker and an entrapped fluorophore by Vero cells showed different fluorescent staining patterns. Specific ⁇ ally, liposomes composed of DPPG/DPPC/Cholesterol (in a ratio of: 50/17/33) gave a punctate pattern of fluores ⁇ cence, while DOPE/Egg PC/Cholesterol (30/37/33) gave a diffuse, homogeneous pattern of fluorescence in the cytoplasm.
  • Liposomes containing 15 ribozymes ( 32 P-labeled) targeted to the HSV ICP4 mRNA were prepared and incubated with the cells. After 24 hours, 25% of the liposome dose was taken up with approximately 60,000 liposomes per cell. Thirty percent of the delivered ribozyme was intact after 24 hours. Cell fractionation studies showed 40% of the intact ribozyme to be in the membrane fraction and 52% of the intact ribozyme to be in the cytoplasmic fraction. In Vivo Assay
  • the efficacy of action of a chosen ribozyme may be tested in vivo using standard procedures in transformed cells or animals which express the target mRNA.
  • antisense riboprobes are transcribed from template DNA using T7 RNA polymerase (U.S. Biochemicals) in 20 ⁇ l reactions containing IX transcrip- tion buffer (supplied by the manufacturer) , 0.2 mM ATP, GTP and UTP, 1 U/ ⁇ l pancreatic RNase inhibitor (Boehringer Mannheim Biochemicals) and 200 ⁇ Ci 32 P-labeled CTP (800 Ci/mmol, New England Nuclear) for 1 hour at 37°C.
  • Template DNA is digested with 1 U RNase-free DNasel (U.S. Biochemicals, Cleveland, OH) at 37°C for 15 minutes and unincorporated nucleotides removed by G-50 SEPHADEX spin chromatography.
  • the target RNA can be transcribed in vi tro using a suitable DNA template.
  • the transcript is purified by standard methods and digested with ribozyme at 37°C according to methods described later.
  • afflicted (mRNA-expressing) cells are harvested into 1 ml of PBS, transferred to a 1.5 ml EPPENDORF tube, pelleted for 30 seconds at low speed in a microcentrifuge, and lysed in 70 ⁇ l of hybridization buffer (4 M guanidine isothiocyanate, 0.1% sarcosyl, 25 mM sodium citrate, pH 7.5) .
  • hybridization buffer 4 M guanidine isothiocyanate, 0.1% sarcosyl, 25 mM sodium citrate, pH 7.5
  • Cell lysate 45 ⁇ l or defined amounts of in vi tro transcript (also in hybridization buffer) is then combined with 5 ⁇ l of hybridization buffer containing 5 x 10 5 cpm of each antisense riboprobe in 0.5 ml Eppendorf tubes, overlaid with 25 ⁇ l mineral oil, and hybridization accomplished by heating overnight at 55°C.
  • hybridization reactions are diluted into 0.5 ml RNase solution (20 U/ml RNaseA, 2 U/ml RNaseTl, 10 U/ml RNase- free DNasel in 0.4 M NaCl) , heated for 30 minutes at 37°C, and 10 ⁇ l of 20% SDS and 10 ⁇ l of Proteinase K (10 mg/ml) added, followed by an additional 30 minutes incubation at 37°C.
  • Hybrids are partially purified by extraction with 0.5 ml of a 1:1 mixture of phenol/chloroform; aqueous phases are combined with 0.5 ml isopropanol, and RNase- resistant hybrids pelleted for 10 minutes at room temperature (about 20°C) in a microcentrifuge.
  • Pellets are dissolved in 10 ⁇ l loading buffer (95% formamide, IX TBE, 0.1% bromophenol blue, 0.1% xylene cylanol) , heated to 95°C for five minutes, cooled on ice, and analyzed on 4% polyacrylamide/7 M urea gels under denaturing conditions.
  • the chosen ribozyme can be tested to determine its stability, and thus its potential utility. Such a test can also be used to determine the effect of various chemical modifications (e.g. , addition of a poly(A) tail) on the ribozyme stability and thus aid selection of a more stable ribozyme.
  • a reaction mixture contains 1 to 5 pmoles of 5' (kinased) and/or 3' labeled ribozyme, 15 ⁇ g of cytosolic extract and 2.5 mM MgCl 2 in a total volume of 100 ⁇ l . The reaction is incubated at 37°C.
  • a 3'-labeled ribozyme can be formed by incorporation of the 32 P-labeled cordycepin at the 3' OH using poly(A) polymerase.
  • the poly(A) polymerase reaction contains 40 mM Tris, pH 8, 10 mM MgCl 2 , 250 mM NaCl, 2.5 mM
  • minor base changes can be made in the substrate cleavage region recognized by a specific ribozyme.
  • the substrate sequences can be changed at the central "C" nucleotide, changing the cleavage site from a GUC to a GUA motif.
  • the K cat /K,,, values for cleavage using each substrate are then analyzed to determine if such a change increases ribozyme cleavage rates. Similar experiments can be performed to address the effects of changing bases comple ⁇ mentary to the ribozyme binding arms. Changes predicted to maintain strong binding to the complementary substrate are preferred. Minor changes in nucleotide content can alter ribozyme/substrate interactions in ways which are unpredictable based upon binding strength alone.
  • Ribozymes are 32 P-end labeled, entrapped in liposomes and delivered to target mRNA-containing cells for three hours.
  • the cells are fractionated and ribozyme is purified by phenol/chloroform extraction.
  • cells lxlO 7 , T-175 flask
  • the cells are homogenized by douncing 35 times in 4 ml of TSE (10 mM Tris, pH 7.4, 0.25 M Sucrose, mM EDTA) . Nuclei are pelleted at lOOxg for 10 minutes.
  • Subcellular organelles are pelleted at 200,000xg for two hours using an SW60 rotor.
  • the pellet is resuspended in 1 ml of H buffer (0.25 M Sucrose, 50 mM HEPES, pH 7.4) .
  • the supernatant contains the cytoplasmic fraction (in approximately 3.7 ml) .
  • the nuclear pellet is resuspended in 1 ml of 65% sucrose in TM
  • the various fractions containing intact ribozyme can be determined.
  • the cells may be fractioned as above and the purity of each fraction assessed by assaying enzyme activity known to exist in that fraction.
  • the various cell fractions are frozen at -70°C and used to determine relative nuclease resistances of modi ⁇ fied ribozyme molecules.
  • Ribozyme molecules may be synthesized with 5 phosphorothioate (ps) , or 2'-0methyl (2'-0Me) modifications at each end of the molecule.
  • ribozyme molecules and a phosphodiester version of the ribozyme are end-labeled with 32 P and ATP using T4 polynucleotide kinase. Equal concentrations are added to the cell cyto ⁇ plasmic extracts and aliquots of each taken at 10 minute intervals. The samples are size fractionated by denatur ⁇ ing PAGE and relative rates of nuclease resistance analyzed by scanning the gel with an Ambis ⁇ -scanner. The results show whether the ribozymes are digested by the cytoplasmic extract, and which versions are relatively more nuclease resistant. Modified ribozymes generally maintain 80-90% of the catalytic activity of the native ribozyme when short RNA substrates are employed. Unlabeled, 5' end-labeled or 3' end-labeled ribozymes can be used in the assays. These experiments can also be performed with human cell extracts to verify the observations.
  • Vero or HeLa cells were grown to 90- 95% confluency in 175 cm 2 tissue culture flasks, scraped into 10 ml of cold phosphate buffered saline (PBS) , then washed once in 10 ml of cold PBS and once in 10 ml of cold TSE (10 mM Tris, pH 7.4; 0.25 M sucrose; 1 mM EDTA) .
  • PBS cold phosphate buffered saline
  • TSE 10 mM Tris, pH 7.4; 0.25 M sucrose; 1 mM EDTA
  • the nuclear pellet was resus ⁇ pended in 1 ml of 65% sucrose TM (50 mM Tris, pH 7.4; 2.5 mM MgCl 2 ) and transferred to Beckman ultra-clear tubes.
  • sucrose TM solutions were layered on top of the sample: 1 ml 60%, 1 ml 55%, and 25% sucrose to the top of the tube. Gradients were spun in an SW60 rotor at 37,000g for 1 hour. HeLa nuclei banded at the 55-60% sucrose boundary and Vero nuclei banded at the 50-55% sucrose boundary.
  • Nuclear bands were harvested, diluted to 10% sucrose with TM buffer, and pelleted by centrifuga ⁇ tion at 37,000g for 15 minutes using an SW60 rotor.
  • the nuclear pellet was resuspended in 1 ml of TM buffer.
  • Subcellular organelles and membrane components in the post nuclear supernatant were separated from the cytoplasmic fraction by centrifugation at 200,000g for 2 hours in an SW60 rotor.
  • the pellet contained the membrane fraction, which was resuspended in 1 ml of H buffer (0.25 M sucrose; 50 mM HEPES, pH 7.4) , and the supernatant contained the cytoplasmic fraction.
  • the assays were as follows: For N-acetyl-beta-hexosaminidase, the reaction mixture contained 0.3 mg/ml 4-methylumbelliferyl-N-acetyl- glucosaminide; 20 mM sodium citrate; pH 4.5; 0.01% Triton
  • the assay medium contained 25 mM CAPS (3- (Cyclohexylamino) -propanesulfonic acid), pH 10.6; 0.05% Triton X-100; 15 mM MgCl 2 ; 1.25 mg/ml Thymidine-5' -monophosphate-p-nitrophenyl ester; and 100 ⁇ l of sample in a total reaction volume of 200 ⁇ l.
  • the reac ⁇ tions were incubated at 37°C for 2 hours, then diluted to 1 ml with H 2 0 and the absorbance was measured at 400 nm (Razell and Khorana, 234 J. Biol . Chem. 739, 1959) .
  • the reaction contained 85 nM sodium citrate, pH 5.9; 0.12% Triton X-100; 0.1% sodium taurocholate; 5 mM 4-methylumbelliferyl ⁇ -O- glucopyranoside; and 125 ⁇ l of sample in a total volume of 250 ⁇ l (Kennedy and Cooper, 252 Biochem. J. 739, 1988) .
  • the reaction was incubated at 37°C for 1 hour and stopped by the addition of 0.75 ml of stop buffer.
  • Product forma ⁇ tion was measured in a fluorescence spectrophotometer by using an excitation wavelength of 360 nm and analysis of the emission at 448 nm.
  • the cytoplasmic enzyme marker, lactate dehydrogenase was assayed in an assay mixture containing 0.2 M Tris; pH 7.4; 0.22 mM NADH; 1 mM sodium pyruvate; and 50 ⁇ l of sample in a final volume of 1.05 ml. Enzyme levels were determined by decreased absorbency at 350 nm resulting from the oxidation of NADH at room temperature (Silverstein and Boyer, 239 J. Biol. Chem. 3901, 1964) .
  • Lactate dehydrogenase was found predominantly in the cytoplasmic fractions of both Vero and HeLa cells, while /3-glucocerebrosidase and alkaline phosphodiesterase were found almost exclusively in the membranous fractions.
  • the hexosaminidase activity in Vero cell fractions was concen ⁇ trated in the membranous fraction (70%) with about 20% in the cytoplasmic fraction.
  • the isolation of enzyme markers with the appropriate cellular compartment demonstrated that cytoplasmic, membranous and nuclear fractions can be isolated with minimal intercompartmental contamination using this fractionation scheme.
  • the basic oligonucleotide digestion reaction contained substrate nucleic acid (an RNA oligo- nucleotide of 36 nucleotides) and cell fraction extract in a total volume of 100 ⁇ l . Aliquots (7 ⁇ l) were taken after various periods of incubation at 37°C and added to 7 ⁇ l of gel loading buffer (95% formamide, 0.1% bromo- phenol blue, 0.1% xylene cyanol, and 20 mM EDTA) . The samples were separated by electrophoresis on a 7 M urea, 20% polyacrylamide gel.
  • substrate nucleic acid an RNA oligo- nucleotide of 36 nucleotides
  • cell fraction extract in a total volume of 100 ⁇ l . Aliquots (7 ⁇ l) were taken after various periods of incubation at 37°C and added to 7 ⁇ l of gel loading buffer (95% formamide, 0.1% bromo- phenol blue, 0.1% xylene cyanol, and 20 m
  • Intact ribozymes were visualized either by staining with Stains-all (United States Biochemical, Cleveland, OH) , or autoradiography of 32 P- labeled ribozyme. The stained gels and X-ray films were scanned on a Bio 5000 density scanner (U.S. Biochemical) . Ribozymes were 5' end-labeled with T4 polynucleotide kinase (U.S. Biochemical) using 10 ⁇ Ci of 32 P ⁇ -ATP (3,000 Ci/mmole, New England Nuclear, Boston, MA) , and 20- 25 pmoles of ribozymes. The unincorporated nucleotides were separated from the product by G-50 spin chromato ⁇ graphy.
  • Nuclease assays contained 1-2 pmoles of 32 P- labeled ribozyme. All oligonucleotides were synthesized on an Applied Biosystems 394 DNA/RNA synthesizer (Applied Biosystems Inc., Foster City, CA) according to manufac- turer's protocols. The nuclear fractions were resuspended in a buffer containing 2.5 mM MgCl 2 . Experiments involving the nuclear fractions were performed in the presence of 1 mM Mg +2 , or in combination with 1 mM Mn +2 , Ca +2 , or Zn + .
  • RNA probes were produced from PCR-amplified template DNA using T7 RNA polymerase (U.S. Biochemical) in the presence of 32 P CU-CTP
  • Hybridization reac- tions were covered with mineral oil and incubated at 55°C for 12-16 hours, after which the hybridization reaction was mixed with 500 ⁇ l of RNase buffer (0.4 M NaCl, 20 ⁇ g/ml RNaseA, 2 units/ml Tl RNase) and incubated for 30 minutes at 37°C. RNase activity was quenched by incuba- tion with 10 ⁇ l of 20% SDS and 10 ⁇ l of proteinase K (20 mg/ml) , and the RNA was extracted using a phenol/ chloroform mixture. The protected RNA fragment was purified by precipitation with an equal volume of isopro ⁇ panol in the presence of 20 ⁇ g of carrier yeast tRNA.
  • RNase buffer 0.4 M NaCl, 20 ⁇ g/ml RNaseA, 2 units/ml Tl RNase
  • RNA pellets were resuspended in gel loading buffer, heated to 95°C for 5 minutes and separated by electrophoresis on a 5% polyacrylamide, 7 M urea gel. Protected fragments were visualized by autoradiography, and the films were scanned with a Bio 5000 density scanner.
  • the rate of digestion of ribozymes in Vero cell extracts was similar, demonstrating the lack of significant phosphatase activity in Vero cellular fractions. Similar results were observed with HeLa cellular fractions. In most extracts, ladders of digested fragments were observed; such ladders would not be expected if digestion was an artifact of phospha ⁇ tase action.
  • digestion using 5' end-labeled ribozymes is an accurate assessment of nuclease action in cellular extracts.
  • labeled ribozymes were incubated in various Vero and HeLa cellular fractions. Incubation of ribozymes in either membranous or nuclear fractions resulted in a linear decrease of intact mole ⁇ cules over time. In contrast, no digestion of ribozymes occurred during a 24 hour incubation in Vero cytoplasmic extracts, and HeLa cytoplasmic extracts exhibited a 20-30 minute delay in the onset of RNA digestion. After this refractory period, the rate of digestion was linear but not as rapid as the rates observed in any of the nuclear or membranous fractions.
  • Vero and HeLa membranous fractions exhibited maximum nuclease activity with the addition of Mg +2 or Mn +2 ions, while the addition of Ca +2 significantly reduced activity of the HeLa membranous fraction and abolished nuclease activity in the Vero membranous fraction.
  • Addition of Zn +2 to both membranous fractions resulted in a loss of all RNase activity.
  • the Vero nuclear extract demonstrated roughly equivalent nuclease activity in the presence of either Mg +2 alone or a Mg +2 and Mn +2 ion combination, less in the presence of Mg +2 and Ca +2 , and no activity in the presence of Mg +2 and Zn +2 .
  • nuclease assays were performed using 1 mM Mg +2 in the presence and absence of 20 mM EDTA.
  • the Mg +2 was replaced with 1 mM Zn +2 .
  • the presence of 20 mM EDTA completely abolished nuclease activity in the Vero and HeLa cyto ⁇ plasmic fractions and Vero nuclear fractions.
  • Nuclease activity in the HeLa membranous and nuclear fractions was partially inhibited by the addition of EDTA, while EDTA had no effect on the nuclease activity in the Vero mem ⁇ branous fraction.
  • reactions using DNA oligonucleotides were performed using different Vero fractions. All DNase activity in Vero cytoplasmic, membranous, and nuclear fractions was inhibited by 20 mM EDTA.
  • RNA oligonucleotides and HSV-1 mRNA were compared in the presence and absence of activity- enhancing divalent cations (1 mM Mg +2 , Vero cells; 1 mM Zn +2 , HeLa cells) .
  • Total cellular RNA from HSV-1 infected Vero cells (8 mg) and tracer amounts of 32 P-5' -end-labeled RNA oligonucleotides (1 pmole) were incubated with Vero or HeLa cytoplasmic extracts. In the absence of divalent cations, no substantial decrease of intact ribozymes was detected in assays, although mRNA was digested in both Vero and HeLa cytoplasmic extracts.
  • HeLa mem ⁇ branous and nuclear fractions were also activated by Mg +2 , while the cytoplasmic fractions required Zn +2 for nuclease activation.
  • Relative stabilities of ribozymes and mRNAs were compared in Vero and HeLa cytoplasmic fractions. In the absence of appropriate divalent cations, little ribo ⁇ zyme digestion was observed in either cytoplasmic prepara ⁇ tion while mRNA was rapidly digested.
  • the addition of Mg +2 to Vero cytoplasmic extracts and Zn +2 to the HeLa cyto ⁇ plasmic extracts stimulated ribozyme degradation and enhanced mRNA digestion.
  • nuclease sensitivity of ribozymes is cell-type specific, varies with the intracellular compartment studied and may not be able to be predicted from studies with mRNA. Notably, however, ribozymes appear stable in such cellular fractions for a period of time potentially sufficient to have a therapeutically useful activity.
  • Selected ribozymes can be administered prophylactic- ally, or to patients having fibrous or connective tissue disorders, e.g. , by exogenous delivery of the ribozyme to a desired tissue by means of an appropriate delivery vehicle, e.g. , a liposome, a controlled release vehicle, by use of iontophoresis, electroporation or ion paired molecules, or covalently attached adducts, and other pharmacologically approved methods of delivery.
  • routes of administration include intramuscular, aerosol, oral (tablet or pill form) , topical, systemic, ocular, intra- peritoneal and/or intrathecal.
  • Expression vectors for immunization with ribozymes and/or delivery of ribozymes are also suitable.
  • any selected ribozyme will depend on the use of the ribozyme. Generally, a specific delivery program for each ribozyme will focus on unmodified ribozyme uptake with regard to intracellular localization, followed by demonstration of efficacy. Alternatively, delivery to these same cells in an organ or tissue of an animal can be pursued. Uptake studies will include uptake assays to evaluate cellular ribozyme uptake, regardless of the delivery vehicle or strategy. Such assays will also determine the intracellular locali ⁇ zation of the ribozyme following uptake, ultimately establishing the requirements for maintenance of steady- state concentrations within the cellular compartment containing the target sequence (nucleus and/or cytoplasm) .
  • Toxicity will not only include cell viability but also cell function.
  • Some methods of delivery that may be used include: a. encapsulation in liposomes, b. transduction by retroviral vectors, c. conjugation with cholesterol, d. localization to nuclear compartment utilizing nuclear targeting site found on most nuclear proteins, e. neutralization of charge of ribozyme by using nucleotide derivatives, and f. use of blood stem cells to distribute ribozymes throughout the body.
  • ribozyme modifications like most small molecules, are taken up by cells, albeit slowly.
  • the ribozyme may be modified essentially at random, in ways which reduce its charge but maintains specific functional groups. This results in a molecule which is able to diffuse across the cell membrane, thus removing the permeability barrier.
  • Modification of ribozymes to reduce charge is just one approach to enhance the cellular uptake of these larger molecules.
  • the random approach is not advisable since ribozymes are structurally and function- ally more complex than small drug molecules.
  • the structural requirements necessary to maintain ribozyme catalytic activity are well understood by those in the art . These requirements are taken into consideration when designing modifications to enhance cellular delivery.
  • the modifications are also designed to reduce susceptibility, to nuclease degradation. Both of these characteristics should greatly improve the efficacy of the ribozyme.
  • Cellular uptake can be increased by several orders of magnitude without having to alter the phosphodiester linkages necessary for ribozyme cleavage activity.
  • Drug delivery vehicles are effective for both systemic and topical administration. They can be designed to serve as a slow release reservoir, or to deliver their contents directly to the target cell.
  • An advantage of using direct delivery drug vehicles is that multiple molecules are delivered per uptake. Such vehicles have been shown to increase the circulation half-life of drugs which would otherwise be rapidly cleared from the blood stream.
  • Some examples of such specialized drug delivery vehicles which fall into this category are liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres.
  • liposomes are preferred. Liposomes increase intracellular stability, increase uptake efficiency and improve biological activity. Liposomes are hollow spherical vesicles composed of lipids arranged in a similar fashion as those lipids which make up the cell membrane. They have an internal aqueous space for entrapping water soluble compounds and range in size from 0.05 to several microns in diameter. Several studies have shown that liposomes can deliver RNA to cells and that the RNA remains biologically active.
  • Lipofectin a liposome delivery vehicle originally designed as a research tool, Lipofectin, has been shown to deliver intact mRNA molecules to cells yielding production of the corresponding protein.
  • Liposomes offer several advantages : They are non- toxic and biodegradable in composition; they display long circulation half-lives; and recognition molecules can be readily attached to their surface for targeting to tissues. Finally, cost effective manufacture of liposome- based pharmaceuticals, either in a liquid suspension or lyophilized product, has demonstrated the viability of this technology as an acceptable drug delivery system.
  • Other controlled release drug delivery systems such as nonoparticles and hydrogels may be potential delivery vehicles for a ribozyme. These carriers have been developed for chemotherapeutic agents and protein-based pharmaceuticals, and consequently, can be adapted for ribozyme delivery.
  • Topical administration of ribozymes is advantageous since it allows localized concentration at the site of administration with minimal systemic adsorption. This simplifies the delivery strategy of the ribozyme to the disease site and reduces the extent of toxicological characterization. Furthermore, the amount of material to be applied is far less than that required for other administration routes. Effective delivery requires the ribozyme to diffuse into the infected cells. Chemical modification of the ribozyme to neutralize negative charge may be all that is required for penetration. However, in the event that charge neutralization is insufficient, the modified ribozyme can be co-formulated with permeability enhancers, such as Azone or oleic acid, in a liposome.
  • permeability enhancers such as Azone or oleic acid
  • the liposomes can either represent a slow release presen ⁇ tation vehicle in which the modified ribozyme and perme- ability enhancer transfer from the liposome into the infected cell, or the liposome phospholipids can partici ⁇ pate directly with the modified ribozyme and permeability enhancer in facilitating cellular delivery.
  • both the ribozyme and permeability enhancer can be formulated into a suppository formulation for slow release.
  • Ribozymes may also be systemically administered.
  • Systemic absorption refers to the accumulation of drugs in the blood stream followed by distribution throughout the entire body.
  • Administration routes which lead to systemic absorption include: intravenous, subcutaneous, intraperi- toneal, intranasal, intrathecal and ophthalmic. Each of these administration routes expose the ribozyme to an accessible diseased tissue.
  • Subcutaneous administration drains into a localized lymph node which proceeds through the lymphatic network into the circulation. The rate of entry into the circulation has been shown to be a function of molecular weight or size.
  • the use of a liposome or other drug carrier localizes the ribozyme at the lymph node.
  • the ribozyme can be modified to diffuse into the cell, or the liposome can directly participate in the delivery of either the unmodified or modified ribozyme to the cell.
  • a liposome formulation containing phosphatidyleth- anolomidomethylthiosuccinimide which can deliver oligo ⁇ nucleotides to lymphocytes and macrophages is useful for certain conditions. Furthermore, a 200 nm diameter liposome of this composition was internalized as well as 100 nm diameter liposomes. The 200 nm liposomes exhibit a ten-fold greater packaging capacity than the 100 nm liposomes and can accomodate larger molecules such as a ribozyme expression vector. This ribozyme delivery system prevents mRNA expression in afflicted primary immune cells.
  • Whole blood studies show that the formulation is taken up by 90% of the lymphocytes after 8 hours at 37°C. Preliminary biodistribution and pharmacokinetic studies yielded 70% of the injected dose/gm of tissue in the spleen after one hour following intravenous administration.
  • Liposomes injected intravenously show accumulation in the liver, lung and spleen.
  • the composition and size can be adjusted so that this accumulation represents 30% to 40% of the injected dose.
  • the remaining dose circulates in the blood stream for up to 24 hours.
  • the chosen method of delivery should result in cytoplasmic accumulation and molecules should have some nuclease-resistance for optimal dosing.
  • Nuclear delivery may be used but is less preferable.
  • Most preferred deliv ⁇ ery methods include liposomes (10-400 nm) , hydrogels, controlled-release polymers, microinjection or electropor- ation (for ex vivo treatments) and other pharmaceutically applicable vehicles.
  • the dosage will depend upon the disease indication and the route of administration but should be between 100-200 mg/kg of body weight/day.
  • the duration of treatment will extend through the course of the disease symptoms, possibly continuously.
  • the number of doses will depend upon disease delivery vehicle and efficacy data from clinical trials.
  • ribozyme within the cell is dependent upon the rate of uptake and degradation. Decreasing the degree of degradation will prolong the intracellular half-life of the ribozyme.
  • chemically modified ribozymes e.g. , with modifica ⁇ tion of the phosphate backbone, or capping of the 5' and 3' ends of the ribozyme with nucleotide analogs may require different dosaging. Descriptions of useful systems are provided in the art cited above, all of which is hereby incorporated by reference herein.

Abstract

An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of fibrous or connective tissue disease.

Description

DESCRIPTION ENZYMATIC RNA MOLECULES AND THEIR APPLICATION IN THE TREATMENT OF FIBROSIS AND FIBROUS TISSUE DISEASE
Background of the Invention
This invention relates to methods for inhibition of fibrous and connective tissue disease, in particular the inhibition of genetic expression which leads to the reduction or elimination of unwanted fibrous or connective tissue during wound healing, tissue remodeling or the growth of fibromatous tissues.
Cellular activities such as differentiation, wound healing, matrix deposition, embryogenesis, bone remodeling and proliferation each involve complex cascades of genetic regulation which are controlled by soluble and intrinsic membrane proteins which serve related, pleiotropic roles in these processes. Transforming growth factor β is perhaps the most ubiquitous and pleiotropic member of the cellular repertoire of cytokines which are involved in the regulation of cell growth. At least five isoforms of TGF jβ are reported and a number of these exhibit tissue specific or differentiation specific expresssion.
Summary of the Invention The invention features use of ribozymes to treat or prevent fibrous and connective tissue disease, e.g. , by inhibiting the synthesis of transforming growth factor beta (TGF-/3) . Cleavage of targeted mRNAs (transforming growth factor beta mRNAs) expressed in keratinocytes, T- lymphocytes, monocytes, macrophages or muscle cells inhibits the synthesis of transforming growth factor β . Those skilled in the art will recognize the other poten¬ tial targets noted above are also suitable for treatment with ribozymes, which will reduce the risk or occurrence of connective and fibrous tissue disease, such as epi¬ dermal growth factor (EGF) , inhibins, activins, transforming growth factor alpha (TGF-cx) , amphiregulin
(AR) , bone morphogenic proteins (BMPs) , fibroblast growth factors (aFGF, bFGF) , and insulin-like growth factors
(IGF-1, -2, insulin, relaxin) . Ribozymes are RNA molecules having an enzymatic activity which is able to repeatedly cleave other separate
RNA molecules in a nucleotide base sequence specific manner. It is said that such enzymatic RNA molecules can be targeted to virtually any RNA transcript and efficient cleavage has been achieved in vi tro . Kim et al . , 84 Proc. Natl. Acad. of Sci. USA 8788, 1987; Haseloff and Gerlach, 334 Nature 585, 1988; Cech, 260 JAMA 3030, 1988; and Jefferies et al. , 17 Nucleic Acids Research 1371, 1989.
Ribozymes act by first binding to a target RNA. Such binding occurs through the target RNA binding portion of a ribozyme which is held in close proximity to an enzym¬ atic portion of the RNA which acts to cleave the target RNA. Thus, the ribozyme first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After a ribozyme has bound and cleaved its RNA target it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.
The enzymatic nature of a ribozyme is advantageous over other technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its translation) since the effective concentration of ribozyme necessary to effect a thera¬ peutic treatment is lower than that of an antisense oligonucleotide. This advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity is defined as the ratio of the rate of cleavage of the targeted RNA over the rate of cleavage of non-targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base pairing. Thus, it is thought that the specificity of action of a ribozyme is greater than that of antisense oligonucleotide binding the same RNA site.
This class of chemicals exhibits a high degree of specificity for cleavage of the intended target mRNA. Consequently, the ribozyme agent will only affect cells expressing that particular gene, and will not be toxic to normal tissues.
The invention can be used to treat or prevent (prophylactically) fibrous or connective tissue diseases. The preferred administration protocol is in vivo administration to reduce the level of TGF-/3 activity. Thus, in the first aspect, the invention features an enzymatic RNA molecule (or ribozyme) which cleaves mRNA associated with development or maintenance of a fibrotic or fibromatous condition, e.g. , mRNA encoding TGF-jβl, -β2 , or β3 and in particular, those mRNA targets disclosed in Table 1. mRNA associated with such diseases are readily identified by standard procedures known in the art . For example, genetic mutations which reduce occurence of such diseases indicate a useful target for ribozyme attack.
Table 1 :
TGF-3 mRNA Nucleotide Number Sequence SEP. ID. NO.
78 CCGGCUCUGAGCCGCCCGC ID. NO. 01 . 97 GGGGCCGGCCUCGGCCCGGAGCGG ID. NO. 02
121 AGGAAGGAGUCGCCGAGGA ID. NO. 03 140 GCAGCCUGAGGCCCCAGAGUCUGAGACGAGCC ID. NO. 04
250 AAACUUUUGAGAC ID. NO. 05
269 GUUGCCGCUGGGAGCCGGAGGC ID. NO. 06
308 CGACGCUGCCCCGCGA ID. NO. 07 330 AGGACUUGGGGACCCCAGACC ID. NO. 08
368 GGGACGCUUGCUCCC ID. NO. 09
390 CCCCUACACGGCGUCCCUCAGGCGCCCCCAUUCC I IDD.. N NOO.. 1 100
432 CCUCGGGAGUCGCCGACCCGG ID. NO. 11
494 UGCACGCCGCCUUCAUCCCCGGCC ID. NO. 12 537 CAUCCUAGACCCUUUCUCCUCCAGGAGAC ID. NO. 13
572 CUCUCCGACCUGCCAC ID. NO. 14
594 CCUAUUCAAGACCA ID. NO. 15
608 CCCACCUUCUGGUACCAGAUCGCGCCC ID. NO. 16
629 CGCGCCCAUCUAGGUUAUUUC ID. NO. 17 666 CCCCCGGUCCAAGCCUCCCCUCCACCACUGCGCC I IDD.. N NOO,. 18
719 AGCUUUCCCUC ID. NO. 19
735 CCUCCUACCUUUUGCC ID. NO. 20
757 CCCCCAGCCCCUGCAGGGG ID. NO. 21
782 CUCCCCACCACACCA ID. NO. 22 803 UUCGCGCUCUCGGCAGUGCC ID. NO. 23
833 GCCUCCCCCAUGCCGCCC ID. NO. 24
928 ACUAUCCACCUGCAAGACUAUCGACAUGGAG ID. NO. 25
972 AGCGCAUCGAGGCCA ID. NO. 26
998 AUCCUGUCCAAGCUGC ID. NO. 27 1035 AGGGGGAGGUGCCGCC ID. NO. 28
1071 UGCUCGCCCUGUACAACAGCA ID. NO. 29
1112 GAGAGUGCAGA ID. NO. 30
1128 AGCCCGAGCCUGAGGCCGACUACUACGCCAAGGA I IDD,. NO. 31
1169 CGCGUGCUAAU ID. NO. 32 1192 CAACGAAAUCUAUGACAAGUUCAAGCAGAGUACA ID. NO. 33
1264 AGAAGCGGUACCUGAACC ID. NO. 34
1296 GGGCAGAGCUGCGUCUGCUGAGGAGG ID. NO. 35
1315 GAGGAGGCUCAAGUUAAAAGUG ID. NO. 36
1354 GUACCAGAAAUACAGCAACAAUUCCUGGCGA ID. NO. 37 1394 AACCGGCUGCUGGCACCCAGCGACUCGCCAGAGU ID. NO. 38
1453 UGUGCGGCAGUGGUUGAGCCGUGGAGGGGAA ID. NO. 39
1478 GGGGAAAUUGAGGGCUUUCGCCUUAGCGCCCACU ID. NO. 40 1581 ACCUGGCCACCAUUCAUGGCAUGAACC ID. NO. 41
1625 AUGGCCACCCCGC ID. NO. 42
1643 AGGGCCCAGCAUCUGCAAAGCUCCCGGCACCGCC ID. NO. 43
1687 CACCAACUAUUGC ID. NO. 44 1730 CGGCAGCUGUACAUUG ID. NO. 45
1752 GCAAGGACCUCGGCU ID. NO. 46
1773 GGAUCCACGAGCCCA ID. NO. 47
1782 GCCCAAGGGCUACCAUGCCAACUUCUGCC ID. NO. 48
1818 CCUGCCCCUACAUUUGGA ID. NO. 49 1862 CUGGCCCUGUACAACCAGCAUAACCCGGG ID. NO. 50
1903 GCCGUGCUGCGUGCCGCAGGCGCUGGAGCCGCU ID. NO. 51
1941 UCGUGUACUACG ID. NO. 52
1958 CGCAAGCCCAAGGUGGAG ID. NO. 53
1977 AGCUGUCCAACAUGAUCGUGC ID. NO. 54 2015 UGAGGUCCCGCCCCGCCCC ID. NO. 55
2092 GGCUGUAUUUAAGGACACCGU ID. NO. 56
2153 GACUGCGGAUCUCU ID. NO. 57
2173 UUGGGCGCCUGCCUGGGGUCUCCAUCCC ID. NO. 58
2207 UCCCCCACUCCCACUCCCU ID. NO. 59 2244 CCUCCUGCCUGUCUGCACUA ID. NO. 60
2270 UGCCCGGCAUCAAGGCAC ID. NO. 61
2313 UAGUUAGAUCUAUUUAUUGA ID. NO. 62
2372 UCAUUCAGUCACCAUAGCAACACUCUGAGAU ID. NO. 63
2415 GAUAACACCCAUUUUAAAGGUUGAGGAAACAA ID. NO. 64 2447 GCCCAGAGAGGUUAAGGGA ID. NO. 65
2478 CACCAGGAACCUGCUUUAGUGGGGGAUAG ID. NO. 66
2498 GGGGGAUAGUGAAGAAGACAAUAAAAGAUAGUA ID. NO. 67
By "enzymatic RNA molecule" it is meant an RNA molecule which has complementarity in a substrate binding region to a specified mRNA target, and also has an enzymatic activity which is active to specifically cleave that mRNA. That is, the enzymatic RNA molecule is able to intermolecularly cleave mRNA and thereby inactivate a target mRNA molecule. This complementarity functions to allow sufficient hybridization of the enzymatic RNA molecule to the target RNA to allow the cleavage to occur. One hundred percent complementarity is preferred, but complementarity as low as 50-75% may also be useful in this invention. For in vivo treatment, complementarity between 30 and 45 bases is preferred. In preferred embodiments, the enzymatic RNA molecule is formed in a hammerhead motif, but may also be formed in the motif of a hairpin, hepatitis delta virus, group I intron or RNaseP-like RNA (in association with an RNA guide sequence) . Examples of such hammerhead motifs are described by Rossi et al. , 8 Aids Research and Human Retroviruses 183, 1992, of hairpin motifs by Hampel et al., "RNA Catalyst for Cleaving Specific RNA Sequences", filed September 20, 1989, which is a continuation-in-part of U.S. Serial No. 07/247,100, filed September 20, 1988; Hampel and Tritz, 28 Biochemistry 4929, 1989; and Hampel et al., 18 Nucleic Acids Research 299, 1990, and an example of the hepatitis delta virus motif is described by Perrotta and Been, 31 Biochemistry 16, 1992, of the RNaseP motif by Guerrier-Takada, et al. , 35 Cell 849, 1983, and of the group I intron by Cech et al. , U.S. Patent 4,987,071. These specific motifs are not limiting in the invention and those skilled in the art will recognize that all that is important in an enzymatic RNA molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule.
In a second related aspect, the invention features a mammalian cell which includes an enzymatic RNA molecule as described above. Preferably, the mammalian cell is a human cell.
In a third related aspect, the invention features an expression vector which includes nucleic acid encoding an enzymatic RNA molecule described above, located in the vector, e.g. , in a manner which allows expression of that enzymatic RNA molecule within a mammalian cell . In a fourth related aspect, the invention features a method for treatment of a fibrotic or fibromatous condition by administering to a patient an enzymatic RNA molecule as described above. The invention provides a class of chemical cleaving agents which exhibit a high degree of specificity for the mRNA causative of a psoriatic condition. Such enzymatic RNA molecules can be delivered exogenously or endogenously to infected cells. In the preferred hammerhead motif the small size (less than 40 nucleotides, preferably between 32 and 36 nucleotides in length) of the molecule allows the cost of treatment to be reduced.
The smallest ribozyme delivered for any type of treatment reported to date (by Rossi et al. , 1992, supra) is an in vi tro transcript having a length of 142 nucleotides. Synthesis of ribozymes greater than 100 nucleotides in length is very difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. Delivery of ribozymes by expression vectors is primarily feasible using only ex vivo treatments. This limits the utility of this approach. In this invention, an alternative approach uses smaller ribozyme motifs (e.g. , of the hammerhead structure, shown generally in Fig. 1) and exogenous delivery. The simple structure of these molecules also increases the ability of the ribozyme to invade targeted regions of the mRNA structure. Thus, unlike the situation when the hammerhead structure is included within longer transcripts, there are no non- ribozyme flanking sequences to interfere with correct folding of the ribozyme structure, as well as complementary binding of the ribozyme to the mRNA target.
The enzymatic RNA molecules of this invention can be used to treat fibromatous conditions or fibrous and connective tissue disorders. Such treatment can also be extended to other related genes in nonhuman primates. Affected animals can be treated at the time of fibrotic risk detection, or in a prophylactic manner. This timing of treatment will reduce the chance of further fibrous or connective tissue damage.
Ribozymes of this invention may be used as diagnostic tools to examine genetic drift and mutations within diseased cells. The close relationship between ribozyme activity and the structure of the target RNA allows the detection of mutations in any region of the molecule which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple ribozymes described in this invention, one may map nucleotide changes which are important to RNA structure and function in vi tro, as well as in cells and tissues. Cleavage of* target RNAs with ribozymes may be used to inhibit gene expression and define the role (essentially) of specified gene products in the progression of disease. In this manner, other genetic targets may be defined as important mediators of the disease. These experiments will lead to better treatment of the disease progression by affording the possibility of combinational therapies (e.g. , multiple ribozymes targeted to different genes, ribozymes coupled with known small molecule inhibitors, or intermittent treatment with combinations of ribozymes and/or other chemical or biological molecules) .
Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
Description of the Preferred Embodiments
The drawing will first briefly be described.
Drawing Fig. 1 is a diagrammatic representation of a hammer¬ head motif ribozyme showing stems I, II and III (marked (I) , (II) and (III) respectively) interacting with a target region. The 5' and 3' ends of both ribozyme and target are shown. Dashes indicate base-paired nucleotides. Target Sites
Ribozymes targeting selected regions of mRNA associa¬ ted with fibrous or connective tissue disease are chosen to cleave the target RNA in a manner which preferably inhibits translation of the RNA. Genes are selected such that inhibition of translation will preferably inhibit cell replication, e.g. , by inhibiting production of a necessary protein. Selection of effective target sites within these critical regions of mRNA entails testing the accessibility of the target RNA to hybridization with various oligonucleotide probes. These studies can be performed using RNA probes and assaying accessibility by cleaving the hybrid molecule with RNaseH (see below) . Alternatively, such a study can use ribozyme probes designed from secondary structure predictions of the mRNAs, and assaying cleavage products by polyacrylamide gel electrophoresis (PAGE) , to detect the presence of cleaved and uncleaved molecules.
The following is but one example of a method by which suitable target sites can be identified and is not limit¬ ing in this invention. Generally, the method involves identifying potential cleavage sites for a hammerhead ribozyme, and then testing each of these sites to deter¬ mine their suitability as targets by ensuring that secondary structure formation is minimal.
The mRNA sequences are compared in an appropriate target region. Putative ribozyme cleavage sites are found. These sites represent the preferable sites for hammerhead ribozyme cleavage within these target mRNAs. Short RNA substrates corresponding to each of the mRNA sites are designed. Each substrate is composed of two to three nucleotides at the 5' and 3' ends that will not base pair with a corresponding ribozyme recognition region. The unpaired regions flanked a central region of 12-14 nucleotides to which complementary arms in the ribozyme are designed. The structure of each substrate sequence is predicted using a PC fold computer program. Sequences which give a positive free energy of binding are accepted. Sequences which give a negative free energy are modified by trimming one or two bases from each of the ends. If the modified sequences are still predicted to have a strong secondary structure, they are rejected.
After substrates are chosen, ribozymes are designed to each of the RNA substrates. Ribozyme folding is also analyzed using PC fold.
Ribozyme molecules are sought which form hammerhead motif stem II (see Fig. 1) regions and contain flanking arms which are devoid of intramolecular base pairing. Often the ribozymes are modified by trimming a base from the ends of the ribozyme, or by introducing additional base pairs in stem II to achieve the desired fold. Ribozymes with incorrect folding are rejected. After substrate/ribozyme pairs are found to contain correct intramolecular structures, the molecules are folded together to predict intermolecular interactions. A schematic representation of a ribozyme with its coordinate base pairing to its cognate target sequence is shown in Fig. 1.
Those targets thought to be useful as ribozyme targets can be tested to determine accessibility to nucleic acid probes in a ribonuclease H assay (see below) . This assay provides a quick test of the use of the target site without requiring synthesis of a ribozyme. It can be used to screen for sites most suited for ribozyme attack.
Synthesis of Ribozymes
Ribozymes useful in this invention can be produced by gene transcription as described by Cech, supra, ox by chemical synthesis. Chemical synthesis of RNA is similar to that for DNA synthesis. The additional 2' -OH group in RNA, however, requires a different protecting group strategy to deal with selective 3' -5' internucleotide bond formation, and with RNA susceptibility to degradation in the presence of bases. The recently developed method of RNA synthesis utilizing the t-butyldimethylsilyl group for the protection of the 2' hydroxyl is the most reliable method for synthesis of ribozymes. The method reproduc- ibly yields RNA with the correct 3 '-5' internucleotide linkages, with average coupling yields in excess of 99%, and requires only a two-step deprotection of the polymer. A method, based upon H-phosphonate chemistry of phosphoroamidites gives a relatively lower coupling efficiency than a method based upon phosphoroamidite chemistry. This is a problem for synthesis of DNA as well . A promising approach to scale-up of automatic oligonucleotide synthesis has been described recently for the H-phosphonates. A combination of a proper coupling time and additional capping of "failure" sequences gave high yields in the synthesis of oligodeoxynucleotides in scales in the range of 14 μmoles with as little as 2 equivalents of a monomer in the coupling step. Another alternative approach is to use soluble polymeric supports (e.g. , polyethylene glycols) , instead of the conventional solid supports. This method can yield short oligonucleo- tides in hundred milligram quantities per batch utilizing about 3 equivalents of a monomer in a coupling step. Various modifications to ribozyme structure can be made to enhance the utility of ribozymes. Such modifica¬ tions will enhance shelf-life, half-life in vi tro, stability, and ease of introduction of such ribozymes to the target site, e.g. , to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells.
Exogenous delivery of ribozymes benefits from chemical modification of the backbone, e.g., by the overall negative charge of the ribozyme molecule being reduced to facilitate diffusion across the cell membrane. The present strategies for reducing the oligonucleotide charge include: modification of internucleotide linkages by methylphosphonates, use of phosphoramidites, linking oligonucleotides to positively charged molecules, and creating complex packages composed of oligonucleotides, lipids and specific receptors or effectors for targeted cells. Examples of such modifications include sulfur- containing ribozymes containing phosphorothioates and phosphorodithioates as internucleotide linkages in RNA. Synthesis of such sulfur-modified ribozymes is achieved by use of the sulfur-transfer reagent, 3H-1, 2-benzenedithiol- 3-one 1,1-dioxide. Ribozymes may also contain ribose modified ribonucleotides. Pyrimidine analogues are prepared from uridine using a procedure employing diethyl- amino sulphur trifluoride (DAST) as a starting reagent. Ribozymes can also be either electrostatically or covalently attached to polymeric cations for the purpose of reducing charge. The polymer can be attached to the ribozyme by simply converting the 3'-end to a ribonucleo- side dialdehyde which is obtained by a periodate cleavage of the terminal 2',3'-cis diol system. Depending on the specific requirements for delivery systems, other possible modifications may include different linker arms containing carboxyl, amino or thiol functionalities. Yet further examples include use of methylphosphonates and 2'-0- methylribose and 5' or 3' capping or blocking with m7GpppG or m3 2'2' GpppG.
For example, a kinased ribozyme is contacted with guanosine triphosphate and guanyltransferase to add an m3G cap to the ribozyme. After such synthesis, the ribozyme can be gel purified using standard procedure. To ensure that the ribozyme has the desired activity, it may be tested with and without the 5' cap using standard procedures to assay both its enzymatic activity and its stability.
Synthetic ribozymes, including those containing various modifiers, can be purified by high pressure liquid chromatography (HPLC) . Other liquid chromatography techniques, employing reverse phase columns and anion exchangers on silica and polymeric supports may also be used.
There follows an example of the synthesis of one ribozyme. (See, Dudycz, U.S. Serial No. 07/884,436, filed May 14, 1992, hereby incorporated by reference herein.) A solid phase phosphoramidite chemistry is employed. Monomers used are 2' -tert-butyl-dimethylsilyl cyanoethyl- phosphoramidities of uridine, N-benzoyl-cytosine, N- phenoxyacetyl adenosine and guanosine (Glen Research, Sterling, VA) . Solid phase synthesis is carried out on either an ABI 394 or 38OB DNA/RNA synthesizer using the standard protocol provided with each machine. The only exception is that the coupling step is increased from 10 to 12 minutes. The phosphoramidite concentration is 0.1 M. Synthesis is done on a 1 μmole scale using a 1 μmole RNA reaction column (Glen Research) . The average coupling efficiencies are between 97% and 98% for the 394 model, and between 97% and 99% for the 380B model, as determined by a calorimetric measurement of the released trityl cation.
Blocked ribozymes are cleaved from the solid support
(e.g. , CPG) , and the bases and diphosphoester moiety deprotected in a sterile vial by dry ethanolic ammonia (2 mL) at 55°C for 16 hours. The reaction mixture is cooled on dry ice. Later, the cold liquid is transferred into a sterile screw cap vial and lyophilized.
To remove the 2 ' -tert-butyl-dimethylsilyl groups from the ribozyme, the residue is suspended in 1 M tetra-n- butylammonium fluoride in dry THF (TBAF) , using a 20 fold excess of the reagent for every silyl group, for 16 hours at ambient temperature (about 15-25°C) . The reaction is quenched by adding an equal volume of sterile 1 M triethylamine acetate, pH 6.5. The sample is cooled and concentrated on a SpeedVac to half the initial volume. The ribozymes are purified in two steps by HPLC on a C4 300 A 5 mm DeltaPak column in an acetonitrile gradient. The first step, or "trityl on" step, is a separation of 5' -DMT-protected ribozyme (s) from failure sequences lacking a 5' -DMT group. Solvents used for this step are: A (0.1 M triethylammonium acetate, pH 6.8) and B (aceto- nitrile) . The elution profile is: 20% B for 10 minutes, followed by a linear gradient of 20% B to 50% B over 50 minutes, 50% B for 10 minutes, a linear gradient of 50% B to 100% B over 10 minutes, and a linear gradient of 100% B to 0% B over 10 minutes. The second step is a purification of a completely deblocked ribozyme by a treatment of 2% trifluoroacetic acid on a C4 300 A 5 mm DeltaPak column in an acetonitrile gradient. Solvents used for this second step are: A (0.1 M Triethylammonium acetate, pH 6.8) and B (80% aceto- nitrile, 0.1 M triethylammonium acetate, pH 6.8) . The elution profile is: 5% B for 5 minutes, a linear gradient of 5% B to 15% B over 60 minutes, 15% B for 10 minutes, and a linear gradient of 15% B to 0% B over 10 minutes.
The fraction containing ribozyme is cooled and lyophilized on a SpeedVac. Solid residue is dissolved in a minimum amount of ethanol and sodium perchlorate in acetone. The ribozyme is collected by centrifugation, washed three times with acetone, and lyophilized.
Expression Vector While synthetic ribozymes are preferred in this invention, those produced by expression vectors can also be used. (See, McSwiggen, U.S. Serial No. 07/884,431, filed May 14, 1992, hereby incorporated by reference herein.) In designing a suitable ribozyme expression vector the following factors are important to consider. The final ribozyme must be kept as small as possible to minimize unwanted secondary structure within the ribozyme. A promoter (e.g. , the human cytomegalovirus immediate early promoter or human beta actin promoter) should be chosen to be a relatively strong promoter, and expressible both in vi tro and in vivo (e.g. , the human cytomegalovirus immediate early promoter or human beta actin promoter) . Such a promoter should express the ribozyme at a level suitable to effect production of enough ribozyme to destroy a target RNA, but not at too high a level to prevent other cellular activities from occurring (unless cell death itself is desired) .
A hairpin at the 5' end of the ribozyme is useful to protect the ribozyme from 5'-3' exonucleases. A selected hairpin at the 3' end of the ribozyme gene is useful since it protects the ribozyme from 3' -5' exonuclease activity. One example of a known hairpin is that present on the T7 RNA poly erase system. This signal is about 30 nucleo¬ tides in length. Other 3' hairpins of shorter length can be used to provide good RNA stability. Such hairpins can be inserted within the vector sequences to allow standard ribozymes to be placed in an appropriate orientation and expressed with such sequences attached.
Poly(A) tails are also useful to protect the 3' end of the ribozyme. These can be provided by either includ- ing a poly(A) signal site in the expression vector (to signal a cell to add the poly(A) tail in vivo) , or by introducing a poly(A) sequence directly into the expres¬ sion vector. In the first approach the signal must be located to prevent unwanted secondary structure formation with other parts of the ribozyme. In the second approach, the poly(A) stretch may reduce in size over time when expressed in vivo, and thus the vector may need to be checked over time. Care must be taken in addition of a poly(A) tail which binds poly(A) binding proteins which prevent the ribozyme from acting.
Ribozyme Testing
Once the desired ribozymes are selected, synthesized and purified, they are tested in kinetic and other experi¬ ments to determine their utility. An example of such a procedure is provided below. Preparation of Ribozyme
Crude synthetic ribozyme (typically 350 μg at a time) is purified by separation on a 15% denaturing polyacryl- amide gel (0.75 mm thick, 40 cm long) and visualized by UV shadowing. Once excised, gel slices containing full length ribozyme are soaked in 5 ml gel elution buffer (0.5 M NH4OAc, 1 mM EDTA) overnight with shaking at 4°C. The eluent is desalted over a C-18 matrix (Sep-Pak cartridges, Millipore, Milford, MA) and vacuum dried. The dried RNA is resuspended in 50-100 μl TE (TRIS 10 mM, EDTA 1 mM, pH 7.2) . An aliquot of this solution is diluted 100 fold into 1 ml TE, half of which is used to spectrophotometric- ally quantitate the ribozyme solution. The concentration of this dilute stock is typically 150-800 nM. Purity of the ribozyme is confirmed by the presence of a single band on a denaturing polyacrylamide gel.
A ribozyme may advantageously be synthesized in two or more portions. (See, Mamone, U.S. Serial No. 07/882,689, filed May 11, 1992, hereby incorporated by reference herein.) Each portion of a ribozyme will generally have only limited or no enzymatic activity, and the activity will increase substantially (by at least 5-10 fold) when all portions are ligated (or otherwise juxta¬ posed) together. A specific example of hammerhead ribozyme synthesis is provided below.
The method involves synthesis of two (or more) shorter "half" ribozymes and ligation of them together using T4 RNA ligase. For example, to make a 34 mer ribozyme, two 17 mers are synthesized, one is phosphoryl- ated, and both are gel purified. These purified 17 mers are then annealed to a DNA splint strand complementary to the two 17 mers. (Such a splint is not always necessary.) This DNA splint has a sequence designed to locate the two 17 mer portions with one end of each adjacent each other. The juxtaposed RNA molecules are then treated with T4 RNA ligase in the presence of ATP. The 34 mer RNA so formed is then HPLC purified. Preparation of Substrates
Approximately 10-30 pmoles of unpurified substrate is radioactively 5' end-labeled with T4 polynucleotide kinase using 25 pmoles of [γ-32P] ATP. The entire labeling mix is separated on a 20% denaturing polyacrylamide gel and visualized by autoradiography. The full length band is excised and soaked overnight at 4°C in 100 μl of TE (10 mM Tris-HCl pH 7.6, 0.1 mM EDTA) .
Kinetic Reactions For reactions using short substrates (between 8 and 16 bases) a substrate solution is made IX in assay buffer (75 mM Tris-HCl, pH 7.6; 0.1 mM EDTA, 10 mM MgCl2) such that the concentration of substrate is less than 1 nM. A ribozyme solution (typically 20 nM) is made IX in assay buffer and four dilutions are made using IX assay buffer. Fifteen μl of each ribozyme dilution (i.e. , 20, 16, 12, 8 and 4 nM) is placed in a separate tube. These tubes and the substrate tube are pre-incubated at 37°C for at least five minutes. The reaction is started by mixing 15 μl of substrate into each ribozyme tube by rapid pipetting (note that final ribozyme concentrations are 10, 8, 6, 4, 2 nM) . Five μl aliquots are removed at 15 or 30 second intervals and quenched with 5 μl stop solution (95% formamide, 20 mM EDTA xylene cyanol, and bromphenol blue dyes) . Following the final ribozyme time point, an aliquot of the remaining substrate is removed as a zero ribozyme control .
The samples are separated on either 15% or 20% polyacrylamide gels. Each gel is visualized and quantitated with an Ambis beta scanner (Ambis Systems, San Diego, CA) .
For the most active ribozymes, kinetic analyses are performed in substrate excess to determine K-, and Kcat values. For kinetic reactions with long RNA substrates (greater than 15 bases in length) the substrates are prepared by transcription using T7 RNA polymerase and defined templates containing a T7 promoter, and DNA encoding appropriate nucleotides of the target RNA. The substrate solution is made IX in assay buffer (75 mM Tris- HCI, pH 7.6; 0.1 mM EDTA; 10 mM MgCl2) and contains 58 nanomolar concentration of the long RNA molecules. The reaction is started by addition of gel purified ribozymes to 1 μM concentration. Aliquots are removed at 20, 40, 60, 80 and 100 minutes, then quenched by the addition of 5 μl stop solution. Cleavage products are separated using denaturing PAGE. The bands are visualized and quantitated with an Ambis beta scanner. Kinetic Analysis
A simple reaction mechanism for ribozyme-mediated cleavage is: k-L k2
R + S [R:S] [R:P] → R + P k_.x where R = ribozyme, S = substrate, and P = products. The boxed step is important only in substrate excess . Because ribozyme concentration is in excess over substrate concen¬ tration, the concentration of the ribozyme-substrate complex ( [R:S] ) is constant over time except during the very brief time when the complex is being initially formed, i.e., : dTR:Sl *= 0 dt where t = time, and thus:
(R) (S)kx = (RS) (k2 + }__■ ) .
The rate of the reaction is the rate of disappearance of substrate with time :
Rate = t ' = k2(RS)
Substituting these expressions:
(R) (S)kι. = l/k2 -d(S) (k2 + kx) dt or: -d(S) = JsJga (R) dt
S (k2 + k*-.)
Integrating this expression with respect to time yields:
-In S_ = k,k2 (R) t S0 (k2 + kx) where S0 = initial substrate. Therefore, a plot of the negative log of fraction substrate uncut versus time (in minutes) yields a straight line with slope: slope = k -c, (R) = kobs (k2 + k_) where kobs = observed rate constant. A plot of slope (kobs) versus ribozyme concentration yields a straight line with a slope which is: slope = k -c-2 which is kcat (k2 + kj K^
Using these equations the data obtained from the kinetic experiments provides the necessary information to determine which ribozyme tested is most useful, or active.
Such ribozymes can be selected and tested in in vivo or ex vivo systems.
Liposome Preparation
Lipid molecules are dissolved in a volatile organic solvent (CHC13, methanol, diethylether, ethanol, etc.) . The organic solvent is removed by evaporation. The lipid is hydrated into suspension with 0.Ix phosphate buffered saline (PBS) , then freeze-thawed 3x using liquid nitrogen and incubation at room temperature. The suspension is extruded sequentially through a 0.4 μm, 0.2 μm and 0.1 μm polycarbonate filters at maximum pressure of 800 psi. The ribozyme is mixed with the extruded liposome suspension and lyophilized to dryness. The lipid/ribozyme powder is rehydrated with water to one-tenth the original volume. The suspension is diluted to the minimum volume required for extrusion (0.4 ml for 1.5 ml barrel and 1.5 ml for 10 ml barrel) with IxPBS and re-extruded through 0.4 μm, 0.2 μm, 0.1 μm polycarbonate filters. The liposome entrapped ribozyme is separated from untrapped ribozyme by gel filtration chromatography (SEPHAROSE CL-4B, BIOGEL A5M) . The liposome extractions are pooled and sterilized by filtration through a 0.2 μm filter. The free ribozyme is pooled and recovered by ethanol precipitation. The liposome concentration is determined by incorporation of a radioactive lipid. The ribozyme concentration is determined by labeling with 32P. Rossi et al. , 1992, supra (and references cited therein) describe other methods suitable for preparation of liposomes. Examples of other useful liposome preparations which display similar degrees of uptake of both a radioactive lipid marker and an entrapped fluorophore by Vero cells showed different fluorescent staining patterns. Specific¬ ally, liposomes composed of DPPG/DPPC/Cholesterol (in a ratio of: 50/17/33) gave a punctate pattern of fluores¬ cence, while DOPE/Egg PC/Cholesterol (30/37/33) gave a diffuse, homogeneous pattern of fluorescence in the cytoplasm. Cell fractionation showed that 80% of the entrapped contents from the DPPG/DPPC/Cholesterol formula- tion was localized in the membrane fraction, whereas the DOPE/Egg PC/Cholesterol formulation was localized in the cytoplasm. Further characterization of the latter formu¬ lation showed that after 3 hours, 70% of the fluorescence was cytoplasmic and 30% was in the membrane. After 24 hours, uptake had increased 5 fold and the liposome contents were distributed 50/50 between the cytoplasmic and membrane fractions.
Liposomes containing 15 ribozymes (32P-labeled) targeted to the HSV ICP4 mRNA were prepared and incubated with the cells. After 24 hours, 25% of the liposome dose was taken up with approximately 60,000 liposomes per cell. Thirty percent of the delivered ribozyme was intact after 24 hours. Cell fractionation studies showed 40% of the intact ribozyme to be in the membrane fraction and 52% of the intact ribozyme to be in the cytoplasmic fraction. In Vivo Assay
The efficacy of action of a chosen ribozyme may be tested in vivo using standard procedures in transformed cells or animals which express the target mRNA.
Ribonuclease Protection Assay
The accumulation of target mRNA in cells or the cleavage of the RNA by ribozymes or RNaseH { in vi tro or in vivo) can be quantified using an RNase protection assay. (See, McSwiggen, U.S. Serial Nos. 07/883,849 and 07/884,073, both filed May 14, 1992, hereby incorporated by reference herein.)
In this method, antisense riboprobes are transcribed from template DNA using T7 RNA polymerase (U.S. Biochemicals) in 20 μl reactions containing IX transcrip- tion buffer (supplied by the manufacturer) , 0.2 mM ATP, GTP and UTP, 1 U/μl pancreatic RNase inhibitor (Boehringer Mannheim Biochemicals) and 200 μCi 32P-labeled CTP (800 Ci/mmol, New England Nuclear) for 1 hour at 37°C. Template DNA is digested with 1 U RNase-free DNasel (U.S. Biochemicals, Cleveland, OH) at 37°C for 15 minutes and unincorporated nucleotides removed by G-50 SEPHADEX spin chromatography.
In a manner similar to the transcription of antisense probe, the target RNA can be transcribed in vi tro using a suitable DNA template. The transcript is purified by standard methods and digested with ribozyme at 37°C according to methods described later.
Alternatively, afflicted (mRNA-expressing) cells are harvested into 1 ml of PBS, transferred to a 1.5 ml EPPENDORF tube, pelleted for 30 seconds at low speed in a microcentrifuge, and lysed in 70 μl of hybridization buffer (4 M guanidine isothiocyanate, 0.1% sarcosyl, 25 mM sodium citrate, pH 7.5) . Cell lysate (45 μl) or defined amounts of in vi tro transcript (also in hybridization buffer) is then combined with 5 μl of hybridization buffer containing 5 x 105 cpm of each antisense riboprobe in 0.5 ml Eppendorf tubes, overlaid with 25 μl mineral oil, and hybridization accomplished by heating overnight at 55°C. The hybridization reactions are diluted into 0.5 ml RNase solution (20 U/ml RNaseA, 2 U/ml RNaseTl, 10 U/ml RNase- free DNasel in 0.4 M NaCl) , heated for 30 minutes at 37°C, and 10 μl of 20% SDS and 10 μl of Proteinase K (10 mg/ml) added, followed by an additional 30 minutes incubation at 37°C. Hybrids are partially purified by extraction with 0.5 ml of a 1:1 mixture of phenol/chloroform; aqueous phases are combined with 0.5 ml isopropanol, and RNase- resistant hybrids pelleted for 10 minutes at room temperature (about 20°C) in a microcentrifuge. Pellets are dissolved in 10 μl loading buffer (95% formamide, IX TBE, 0.1% bromophenol blue, 0.1% xylene cylanol) , heated to 95°C for five minutes, cooled on ice, and analyzed on 4% polyacrylamide/7 M urea gels under denaturing conditions.
Ribozyme Stability
The chosen ribozyme can be tested to determine its stability, and thus its potential utility. Such a test can also be used to determine the effect of various chemical modifications (e.g. , addition of a poly(A) tail) on the ribozyme stability and thus aid selection of a more stable ribozyme. For example, a reaction mixture contains 1 to 5 pmoles of 5' (kinased) and/or 3' labeled ribozyme, 15 μg of cytosolic extract and 2.5 mM MgCl2 in a total volume of 100 μl . The reaction is incubated at 37°C. Eight μl aliquots are taken at timed intervals and mixed with 8 μl of a stop mix (20 mM EDTA, 95% formamide) . Samples are separated on a 15% acrylamide sequencing gel, exposed to film, and scanned with an Ambis.
A 3'-labeled ribozyme can be formed by incorporation of the 32P-labeled cordycepin at the 3' OH using poly(A) polymerase. For example, the poly(A) polymerase reaction contains 40 mM Tris, pH 8, 10 mM MgCl2, 250 mM NaCl, 2.5 mM
MnCl2, ; 3 μl 32P cordycepin, 500 Ci/mM; and 6 units poly(A) polymerase in a total volume of 50 μl . The reaction mixture is incubated for 30 minutes at 37°C.
Effect of base substitution upon Ribozyme Activity
To determine which primary structural characteristics could change ribozyme cleavage of substrate, minor base changes can be made in the substrate cleavage region recognized by a specific ribozyme. For example, the substrate sequences can be changed at the central "C" nucleotide, changing the cleavage site from a GUC to a GUA motif. (See, McSwiggen, U.S. Serial No. 07/884,074, filed May 14, 1992, hereby incorporated by reference herein.) The Kcat/K,,, values for cleavage using each substrate are then analyzed to determine if such a change increases ribozyme cleavage rates. Similar experiments can be performed to address the effects of changing bases comple¬ mentary to the ribozyme binding arms. Changes predicted to maintain strong binding to the complementary substrate are preferred. Minor changes in nucleotide content can alter ribozyme/substrate interactions in ways which are unpredictable based upon binding strength alone.
Structures in the catalytic core region of the ribozyme recognize trivial changes in either substrate structure or the three dimensional structure of the ribozyme/substrate complex. To begin optimizing ribozyme design, the cleavage rates of ribozymes containing varied arm lengths, but targeted to the same length of short RNA substrate can be tested. Minimal arm lengths are required and effective cleavage varies with ribozyme/substrate combinations. The cleavage activity of selected ribozymes can be assessed using target mRNA substrates. The assays are performed in ribozyme excess and approximate K^/K^ values obtained. Comparison of values obtained with short and long substrates indicates utility in vivo of a ribozyme. Intracellular Stability of liposome-delivered ribozymes
To test the stability of a chosen ribozyme in vivo the following test is useful. Ribozymes are 32P-end labeled, entrapped in liposomes and delivered to target mRNA-containing cells for three hours. The cells are fractionated and ribozyme is purified by phenol/chloroform extraction. Alternatively, cells (lxlO7, T-175 flask) are scraped from the surface of the flask and washed twice with cold PBS. The cells are homogenized by douncing 35 times in 4 ml of TSE (10 mM Tris, pH 7.4, 0.25 M Sucrose, mM EDTA) . Nuclei are pelleted at lOOxg for 10 minutes. Subcellular organelles (the membrane fraction) are pelleted at 200,000xg for two hours using an SW60 rotor. The pellet is resuspended in 1 ml of H buffer (0.25 M Sucrose, 50 mM HEPES, pH 7.4) . The supernatant contains the cytoplasmic fraction (in approximately 3.7 ml) . The nuclear pellet is resuspended in 1 ml of 65% sucrose in TM
(50 mM Tris, pH 7.4, 2.5 mM MgCl2) and banded on a sucrose step gradient (1 ml nuclei in 65% sucrose TM, 1 ml 60% sucrose TM, 1 ml 55% sucrose TM, 50% sucrose TM, 300 μl 25% sucrose TM) for one hour at 37,000xg with an SW60 rotor. The nuclear band is harvested and diluted to 10% sucrose with TM buffer. Nuclei are pelleted at 37,000xg using an SW60 rotor for 15 minutes and the pellet resus- pended in 1 ml of TM buffer. Aliquots are size fraction¬ ated on denaturing polyacrylamide gels and the intra¬ cellular localization determined. By comparison to the migration rate of newly synthesized ribozyme, the various fractions containing intact ribozyme can be determined. To investigate modifications which would lengthen the half-life of ribozyme molecules intracellularly, the cells may be fractioned as above and the purity of each fraction assessed by assaying enzyme activity known to exist in that fraction. The various cell fractions are frozen at -70°C and used to determine relative nuclease resistances of modi¬ fied ribozyme molecules. Ribozyme molecules may be synthesized with 5 phosphorothioate (ps) , or 2'-0methyl (2'-0Me) modifications at each end of the molecule. These molecules and a phosphodiester version of the ribozyme are end-labeled with 32P and ATP using T4 polynucleotide kinase. Equal concentrations are added to the cell cyto¬ plasmic extracts and aliquots of each taken at 10 minute intervals. The samples are size fractionated by denatur¬ ing PAGE and relative rates of nuclease resistance analyzed by scanning the gel with an Ambis β-scanner. The results show whether the ribozymes are digested by the cytoplasmic extract, and which versions are relatively more nuclease resistant. Modified ribozymes generally maintain 80-90% of the catalytic activity of the native ribozyme when short RNA substrates are employed. Unlabeled, 5' end-labeled or 3' end-labeled ribozymes can be used in the assays. These experiments can also be performed with human cell extracts to verify the observations.
In one example, Vero or HeLa cells were grown to 90- 95% confluency in 175 cm2 tissue culture flasks, scraped into 10 ml of cold phosphate buffered saline (PBS) , then washed once in 10 ml of cold PBS and once in 10 ml of cold TSE (10 mM Tris, pH 7.4; 0.25 M sucrose; 1 mM EDTA) . The cell pellets were resuspended in 4 ml of TSE, dounced 35x on ice, and the released nuclei pelleted by centrifugation at lOOOg for 10 minutes. The nuclear pellet was resus¬ pended in 1 ml of 65% sucrose TM (50 mM Tris, pH 7.4; 2.5 mM MgCl2) and transferred to Beckman ultra-clear tubes. The following sucrose TM solutions were layered on top of the sample: 1 ml 60%, 1 ml 55%, and 25% sucrose to the top of the tube. Gradients were spun in an SW60 rotor at 37,000g for 1 hour. HeLa nuclei banded at the 55-60% sucrose boundary and Vero nuclei banded at the 50-55% sucrose boundary. Nuclear bands were harvested, diluted to 10% sucrose with TM buffer, and pelleted by centrifuga¬ tion at 37,000g for 15 minutes using an SW60 rotor. The nuclear pellet was resuspended in 1 ml of TM buffer. Subcellular organelles and membrane components in the post nuclear supernatant were separated from the cytoplasmic fraction by centrifugation at 200,000g for 2 hours in an SW60 rotor. The pellet contained the membrane fraction, which was resuspended in 1 ml of H buffer (0.25 M sucrose; 50 mM HEPES, pH 7.4) , and the supernatant contained the cytoplasmic fraction.
Purity of the various fractions was assessed using enzymatic markers specific for the cytoplasmic and mem- branous fractions. Three enzyme markers for the membranous fraction were used; hexosaminidase and β- glucocerebrosidase are localized in lysosomes, while alkaline phosphodiesterase is specific to endosomes. Specifically, the assays were as follows: For N-acetyl-beta-hexosaminidase, the reaction mixture contained 0.3 mg/ml 4-methylumbelliferyl-N-acetyl- glucosaminide; 20 mM sodium citrate; pH 4.5; 0.01% Triton
X-100; and 100 μl of sample in a final volume of 500 μl
(Harding et al. , 64 Cell 393, 1991) . The reactions were incubated at 37°C for 1 hour and stopped by the addition of 1.5 ml of stop buffer (0.13 M glycine, 0.07 M NaCl, 0.08 M sodium carbonate, pH 10.6) . The reaction product was quantitated in a Hitachi F-4010 fluorescence spectro- photometer by excitation of the fluorophore at 360 nm and analysis of the emission at 448 nm.
For Alkaline Phosphodiesterase, the assay medium contained 25 mM CAPS (3- (Cyclohexylamino) -propanesulfonic acid), pH 10.6; 0.05% Triton X-100; 15 mM MgCl2; 1.25 mg/ml Thymidine-5' -monophosphate-p-nitrophenyl ester; and 100 μl of sample in a total reaction volume of 200 μl. The reac¬ tions were incubated at 37°C for 2 hours, then diluted to 1 ml with H20 and the absorbance was measured at 400 nm (Razell and Khorana, 234 J. Biol . Chem. 739, 1959) .
For /S-glucocerebrosidase, the reaction contained 85 nM sodium citrate, pH 5.9; 0.12% Triton X-100; 0.1% sodium taurocholate; 5 mM 4-methylumbelliferyl β-O- glucopyranoside; and 125 μl of sample in a total volume of 250 μl (Kennedy and Cooper, 252 Biochem. J. 739, 1988) . The reaction was incubated at 37°C for 1 hour and stopped by the addition of 0.75 ml of stop buffer. Product forma¬ tion was measured in a fluorescence spectrophotometer by using an excitation wavelength of 360 nm and analysis of the emission at 448 nm.
The cytoplasmic enzyme marker, lactate dehydrogenase, was assayed in an assay mixture containing 0.2 M Tris; pH 7.4; 0.22 mM NADH; 1 mM sodium pyruvate; and 50 μl of sample in a final volume of 1.05 ml. Enzyme levels were determined by decreased absorbency at 350 nm resulting from the oxidation of NADH at room temperature (Silverstein and Boyer, 239 J. Biol. Chem. 3901, 1964) .
Lactate dehydrogenase was found predominantly in the cytoplasmic fractions of both Vero and HeLa cells, while /3-glucocerebrosidase and alkaline phosphodiesterase were found almost exclusively in the membranous fractions. The hexosaminidase activity in Vero cell fractions was concen¬ trated in the membranous fraction (70%) with about 20% in the cytoplasmic fraction. The isolation of enzyme markers with the appropriate cellular compartment demonstrated that cytoplasmic, membranous and nuclear fractions can be isolated with minimal intercompartmental contamination using this fractionation scheme.
Nuclease Stability of Ribozymes and mRNA
The simplest and most sensitive way to monitor nuclease activity in cell fractions is to use end-labeled oligonucleotides. However, high levels of phosphatase activity in some biological extracts gives ambiguous results in nuclease experiments when 32P-5' -end-labeled oligonucleotides are used as substrates. To determine the phosphatase activity in the extracts, cellular fractions were incubated with cold ribozymes and trace amounts of 5' -end-labeled ribozyme in the presence of 1 mM Mg+2 (or Zn+2 with HeLa cytoplasmic extracts) to optimize digestion. After polyacrylamide gel electrophoresis of samples, digestion of the oligonucleotide was assessed both by staining and by autoradiography.
Specifically, the basic oligonucleotide digestion reaction contained substrate nucleic acid (an RNA oligo- nucleotide of 36 nucleotides) and cell fraction extract in a total volume of 100 μl . Aliquots (7 μl) were taken after various periods of incubation at 37°C and added to 7 μl of gel loading buffer (95% formamide, 0.1% bromo- phenol blue, 0.1% xylene cyanol, and 20 mM EDTA) . The samples were separated by electrophoresis on a 7 M urea, 20% polyacrylamide gel. Intact ribozymes were visualized either by staining with Stains-all (United States Biochemical, Cleveland, OH) , or autoradiography of 32P- labeled ribozyme. The stained gels and X-ray films were scanned on a Bio 5000 density scanner (U.S. Biochemical) . Ribozymes were 5' end-labeled with T4 polynucleotide kinase (U.S. Biochemical) using 10 μCi of 32P γ-ATP (3,000 Ci/mmole, New England Nuclear, Boston, MA) , and 20- 25 pmoles of ribozymes. The unincorporated nucleotides were separated from the product by G-50 spin chromato¬ graphy. Nuclease assays contained 1-2 pmoles of 32P- labeled ribozyme. All oligonucleotides were synthesized on an Applied Biosystems 394 DNA/RNA synthesizer (Applied Biosystems Inc., Foster City, CA) according to manufac- turer's protocols. The nuclear fractions were resuspended in a buffer containing 2.5 mM MgCl2. Experiments involving the nuclear fractions were performed in the presence of 1 mM Mg+2, or in combination with 1 mM Mn+2, Ca+2, or Zn+ .
To measure the stability of mRNA, Vero cells were infected with herpes simplex virus (HSV) at a M.O.I, of 5 and total RNA was extracted (Chomczynski and Sacchi, 162 Anal. Biochem. 156, 1987) . An RNase protection assay was used to detect mRNA after incubation of total infected cellular RNA in cytoplasmic extracts. RNA probes were produced from PCR-amplified template DNA using T7 RNA polymerase (U.S. Biochemical) in the presence of 32P CU-CTP
(3,000 Ci/mmole, New England Nuclear, Boston, MA) . Template DNA was inactivated with 1 unit of RNase-free DNasel for 15 minutes at 37°C. Unincorporated nucleotides were removed by G-50 spin chromatography. Samples (6 μl) were taken from the nuclease assays after various periods of incubation at 37°C, added to 40 μl of 4 M GUSCN buffer (4 M guanidinium thiocyanate; 25 mM sodium citrate, pH 7; 0.5% sarcosyl; and 0.1 M 2-mercaptoethanol) , and 5 μl of 32P-labeled RNA probe (5xl05 cpm/5 μl, specific activity of 1.8x10s cpm/μg) in 4 M GUSCN buffer. Hybridization reac- tions were covered with mineral oil and incubated at 55°C for 12-16 hours, after which the hybridization reaction was mixed with 500 μl of RNase buffer (0.4 M NaCl, 20 μg/ml RNaseA, 2 units/ml Tl RNase) and incubated for 30 minutes at 37°C. RNase activity was quenched by incuba- tion with 10 μl of 20% SDS and 10 μl of proteinase K (20 mg/ml) , and the RNA was extracted using a phenol/ chloroform mixture. The protected RNA fragment was purified by precipitation with an equal volume of isopro¬ panol in the presence of 20 μg of carrier yeast tRNA. The RNA pellets were resuspended in gel loading buffer, heated to 95°C for 5 minutes and separated by electrophoresis on a 5% polyacrylamide, 7 M urea gel. Protected fragments were visualized by autoradiography, and the films were scanned with a Bio 5000 density scanner. In experiments using these methods, the rate of digestion of ribozymes in Vero cell extracts was similar, demonstrating the lack of significant phosphatase activity in Vero cellular fractions. Similar results were observed with HeLa cellular fractions. In most extracts, ladders of digested fragments were observed; such ladders would not be expected if digestion was an artifact of phospha¬ tase action. Thus, digestion using 5' end-labeled ribozymes is an accurate assessment of nuclease action in cellular extracts. In other experiments, labeled ribozymes were incubated in various Vero and HeLa cellular fractions. Incubation of ribozymes in either membranous or nuclear fractions resulted in a linear decrease of intact mole¬ cules over time. In contrast, no digestion of ribozymes occurred during a 24 hour incubation in Vero cytoplasmic extracts, and HeLa cytoplasmic extracts exhibited a 20-30 minute delay in the onset of RNA digestion. After this refractory period, the rate of digestion was linear but not as rapid as the rates observed in any of the nuclear or membranous fractions.
The effect of four divalent cations (Mg+2, Mn+2, Ca+2, and Zn+2) on the nuclease activity of the cellular frac¬ tions was assessed. Vero cytoplasmic extracts were stimulated by the addition of 1 mM Mg+2 or Mn+2, while Ca+2 or Zn+2 had no effect. Nuclease activity in HeLa cyto¬ plasmic extracts was enhanced only by the addition of 1 mM Zn+2. Both Vero and HeLa membranous fractions exhibited maximum nuclease activity with the addition of Mg+2 or Mn+2 ions, while the addition of Ca+2 significantly reduced activity of the HeLa membranous fraction and abolished nuclease activity in the Vero membranous fraction. Addition of Zn+2 to both membranous fractions resulted in a loss of all RNase activity. The Vero nuclear extract demonstrated roughly equivalent nuclease activity in the presence of either Mg+2 alone or a Mg+2 and Mn+2 ion combination, less in the presence of Mg+2 and Ca+2, and no activity in the presence of Mg+2 and Zn+2. The effects of cation addition were not as dramatic with HeLa nuclear extracts. The nuclease activity of these fractions was greatest in the presence of Mg+2 alone or Mg+2 and Ca+2 and decreased slightly with the addition of Mn+2 or Zn+2 to the Mg+2 present in the extracts.
To verify that nuclease activity was dependent upon added divalent cations, nuclease assays were performed using 1 mM Mg+2 in the presence and absence of 20 mM EDTA. For the HeLa cytoplasmic fractions, the Mg+2 was replaced with 1 mM Zn+2. The presence of 20 mM EDTA completely abolished nuclease activity in the Vero and HeLa cyto¬ plasmic fractions and Vero nuclear fractions. Nuclease activity in the HeLa membranous and nuclear fractions was partially inhibited by the addition of EDTA, while EDTA had no effect on the nuclease activity in the Vero mem¬ branous fraction. For comparative purposes, reactions using DNA oligonucleotides were performed using different Vero fractions. All DNase activity in Vero cytoplasmic, membranous, and nuclear fractions was inhibited by 20 mM EDTA.
The stability of RNA oligonucleotides and HSV-1 mRNA were compared in the presence and absence of activity- enhancing divalent cations (1 mM Mg+2, Vero cells; 1 mM Zn+2, HeLa cells) . Total cellular RNA from HSV-1 infected Vero cells (8 mg) and tracer amounts of 32P-5' -end-labeled RNA oligonucleotides (1 pmole) were incubated with Vero or HeLa cytoplasmic extracts. In the absence of divalent cations, no substantial decrease of intact ribozymes was detected in assays, although mRNA was digested in both Vero and HeLa cytoplasmic extracts. After addition of divalent cations, digestion of ribozymes occurred in both Vero and HeLa cytoplasmic fractions. The rate of ribozyme digestion in HeLa extracts increased to levels similar to those observed with mRNA, while the rate of mRNA digestion remained greater than the rate of ribozyme digestion in Vero cytoplasmic fractions. Thus, the stability of hammerhead ribozymes were compared in both Vero and HeLa cell cytoplasmic, mem¬ branous and nuclear fractions. Vero cytoplasmic and nuclear fractions were found to require Mg+2 for optimal nuclease activity, while the membranous fraction was not altered by the addition of divalent cations. HeLa mem¬ branous and nuclear fractions were also activated by Mg+2, while the cytoplasmic fractions required Zn+2 for nuclease activation. Relative stabilities of ribozymes and mRNAs were compared in Vero and HeLa cytoplasmic fractions. In the absence of appropriate divalent cations, little ribo¬ zyme digestion was observed in either cytoplasmic prepara¬ tion while mRNA was rapidly digested. The addition of Mg+2 to Vero cytoplasmic extracts and Zn+2 to the HeLa cyto¬ plasmic extracts stimulated ribozyme degradation and enhanced mRNA digestion. These data show that the nuclease sensitivity of ribozymes is cell-type specific, varies with the intracellular compartment studied and may not be able to be predicted from studies with mRNA. Notably, however, ribozymes appear stable in such cellular fractions for a period of time potentially sufficient to have a therapeutically useful activity.
Administration of Ribozyme
Selected ribozymes can be administered prophylactic- ally, or to patients having fibrous or connective tissue disorders, e.g. , by exogenous delivery of the ribozyme to a desired tissue by means of an appropriate delivery vehicle, e.g. , a liposome, a controlled release vehicle, by use of iontophoresis, electroporation or ion paired molecules, or covalently attached adducts, and other pharmacologically approved methods of delivery. Routes of administration include intramuscular, aerosol, oral (tablet or pill form) , topical, systemic, ocular, intra- peritoneal and/or intrathecal. Expression vectors for immunization with ribozymes and/or delivery of ribozymes are also suitable.
The specific delivery route of any selected ribozyme will depend on the use of the ribozyme. Generally, a specific delivery program for each ribozyme will focus on unmodified ribozyme uptake with regard to intracellular localization, followed by demonstration of efficacy. Alternatively, delivery to these same cells in an organ or tissue of an animal can be pursued. Uptake studies will include uptake assays to evaluate cellular ribozyme uptake, regardless of the delivery vehicle or strategy. Such assays will also determine the intracellular locali¬ zation of the ribozyme following uptake, ultimately establishing the requirements for maintenance of steady- state concentrations within the cellular compartment containing the target sequence (nucleus and/or cytoplasm) . Efficacy and cytotoxicity can then be tested. Toxicity will not only include cell viability but also cell function. Some methods of delivery that may be used include: a. encapsulation in liposomes, b. transduction by retroviral vectors, c. conjugation with cholesterol, d. localization to nuclear compartment utilizing nuclear targeting site found on most nuclear proteins, e. neutralization of charge of ribozyme by using nucleotide derivatives, and f. use of blood stem cells to distribute ribozymes throughout the body.
At least three types of delivery strategies are useful in the present invention, including: ribozyme modifications, particle carrier drug delivery vehicles, and retroviral expression vectors. Unmodified ribozymes, like most small molecules, are taken up by cells, albeit slowly. To enhance cellular uptake, the ribozyme may be modified essentially at random, in ways which reduce its charge but maintains specific functional groups. This results in a molecule which is able to diffuse across the cell membrane, thus removing the permeability barrier.
Modification of ribozymes to reduce charge is just one approach to enhance the cellular uptake of these larger molecules. The random approach, however, is not advisable since ribozymes are structurally and function- ally more complex than small drug molecules. The structural requirements necessary to maintain ribozyme catalytic activity are well understood by those in the art . These requirements are taken into consideration when designing modifications to enhance cellular delivery. The modifications are also designed to reduce susceptibility, to nuclease degradation. Both of these characteristics should greatly improve the efficacy of the ribozyme. Cellular uptake can be increased by several orders of magnitude without having to alter the phosphodiester linkages necessary for ribozyme cleavage activity.
Chemical modifications of the phosphate backbone will reduce the negative charge allowing free diffusion across the membrane. This principle has been successfully demon¬ strated for antisense DNA technology. The similarities in chemical composition between DNA and RNA make this a feas¬ ible approach. In the body, maintenance of an external concentration will be necessary to drive the diffusion of the modified ribozyme into the cells of the tissue. Administration routes which allow the diseased tissue to be exposed to a transient high concentration of the drug, which is slowly dissipated by systemic adsorption are preferred. Intravenous administration with a drug carrier designed to increase the circulation half-life of the ribozyme can be used. The size and composition of the drug carrier restricts rapid clearance from the blood stream. The carrier, made to accumulate at the site of infection, can protect the ribozyme from degradative processes.
Drug delivery vehicles are effective for both systemic and topical administration. They can be designed to serve as a slow release reservoir, or to deliver their contents directly to the target cell. An advantage of using direct delivery drug vehicles is that multiple molecules are delivered per uptake. Such vehicles have been shown to increase the circulation half-life of drugs which would otherwise be rapidly cleared from the blood stream. Some examples of such specialized drug delivery vehicles which fall into this category are liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres.
From this category of delivery systems, liposomes are preferred. Liposomes increase intracellular stability, increase uptake efficiency and improve biological activity. Liposomes are hollow spherical vesicles composed of lipids arranged in a similar fashion as those lipids which make up the cell membrane. They have an internal aqueous space for entrapping water soluble compounds and range in size from 0.05 to several microns in diameter. Several studies have shown that liposomes can deliver RNA to cells and that the RNA remains biologically active.
For example, a liposome delivery vehicle originally designed as a research tool, Lipofectin, has been shown to deliver intact mRNA molecules to cells yielding production of the corresponding protein.
Liposomes offer several advantages : They are non- toxic and biodegradable in composition; they display long circulation half-lives; and recognition molecules can be readily attached to their surface for targeting to tissues. Finally, cost effective manufacture of liposome- based pharmaceuticals, either in a liquid suspension or lyophilized product, has demonstrated the viability of this technology as an acceptable drug delivery system. Other controlled release drug delivery systems, such as nonoparticles and hydrogels may be potential delivery vehicles for a ribozyme. These carriers have been developed for chemotherapeutic agents and protein-based pharmaceuticals, and consequently, can be adapted for ribozyme delivery.
Topical administration of ribozymes is advantageous since it allows localized concentration at the site of administration with minimal systemic adsorption. This simplifies the delivery strategy of the ribozyme to the disease site and reduces the extent of toxicological characterization. Furthermore, the amount of material to be applied is far less than that required for other administration routes. Effective delivery requires the ribozyme to diffuse into the infected cells. Chemical modification of the ribozyme to neutralize negative charge may be all that is required for penetration. However, in the event that charge neutralization is insufficient, the modified ribozyme can be co-formulated with permeability enhancers, such as Azone or oleic acid, in a liposome. The liposomes can either represent a slow release presen¬ tation vehicle in which the modified ribozyme and perme- ability enhancer transfer from the liposome into the infected cell, or the liposome phospholipids can partici¬ pate directly with the modified ribozyme and permeability enhancer in facilitating cellular delivery. In some cases, both the ribozyme and permeability enhancer can be formulated into a suppository formulation for slow release.
Ribozymes may also be systemically administered. Systemic absorption refers to the accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes which lead to systemic absorption include: intravenous, subcutaneous, intraperi- toneal, intranasal, intrathecal and ophthalmic. Each of these administration routes expose the ribozyme to an accessible diseased tissue. Subcutaneous administration drains into a localized lymph node which proceeds through the lymphatic network into the circulation. The rate of entry into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier localizes the ribozyme at the lymph node. The ribozyme can be modified to diffuse into the cell, or the liposome can directly participate in the delivery of either the unmodified or modified ribozyme to the cell.
A liposome formulation containing phosphatidyleth- anolomidomethylthiosuccinimide which can deliver oligo¬ nucleotides to lymphocytes and macrophages is useful for certain conditions. Furthermore, a 200 nm diameter liposome of this composition was internalized as well as 100 nm diameter liposomes. The 200 nm liposomes exhibit a ten-fold greater packaging capacity than the 100 nm liposomes and can accomodate larger molecules such as a ribozyme expression vector. This ribozyme delivery system prevents mRNA expression in afflicted primary immune cells. Whole blood studies show that the formulation is taken up by 90% of the lymphocytes after 8 hours at 37°C. Preliminary biodistribution and pharmacokinetic studies yielded 70% of the injected dose/gm of tissue in the spleen after one hour following intravenous administration.
Liposomes injected intravenously show accumulation in the liver, lung and spleen. The composition and size can be adjusted so that this accumulation represents 30% to 40% of the injected dose. The remaining dose circulates in the blood stream for up to 24 hours.*
The chosen method of delivery should result in cytoplasmic accumulation and molecules should have some nuclease-resistance for optimal dosing. Nuclear delivery may be used but is less preferable. Most preferred deliv¬ ery methods include liposomes (10-400 nm) , hydrogels, controlled-release polymers, microinjection or electropor- ation (for ex vivo treatments) and other pharmaceutically applicable vehicles. The dosage will depend upon the disease indication and the route of administration but should be between 100-200 mg/kg of body weight/day. The duration of treatment will extend through the course of the disease symptoms, possibly continuously. The number of doses will depend upon disease delivery vehicle and efficacy data from clinical trials.
Establishment of therapeutic levels of ribozyme within the cell is dependent upon the rate of uptake and degradation. Decreasing the degree of degradation will prolong the intracellular half-life of the ribozyme. Thus, chemically modified ribozymes, e.g. , with modifica¬ tion of the phosphate backbone, or capping of the 5' and 3' ends of the ribozyme with nucleotide analogs may require different dosaging. Descriptions of useful systems are provided in the art cited above, all of which is hereby incorporated by reference herein.
Other embodiments are within the following claims. "Sequence Listing" (1) GENERAL INFORMATION: (i) APPLICANT: Kenneth G. Draper (ii) TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT OF FIBROSIS AND FIBROUS TISSUE DISEASE
(iii) NUMBER OF SEQUENCES: 67 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Lyon & Lyon
(B) STREET: 611 West Sixth Street
(C) CITY: Los Angeles
(D) STATE: California
(E) COUNTRY: USA
(F) ZIP: 90017
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: 3.5" Disk, 1.44 Mb storage
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: IBM MS-DOS (Version 5.0)
(D) SOFTWARE: WordPerfect (Version 5.1)
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
Prior applications total, including application described below: none
(A) APPLICATION NUMBER:
(B) FILING DATE:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Warburg, Richard J.
(B) REGISTRATION NUMBER: 32,327
(C) REFERENCE/DOCKET NUMBER: 202/115
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (213) 489-1600 (B) TELEFAX: (213) 955-0440 (C) TELEX: 67-3510 (2) INFORMATION FOR SEQ ID NO: 1 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 19
(B) TYPE: nucleic acid
(C) STRANDEDNESS : single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 1: CCGGCUCUGA GCCGCCCGC 19
(2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 2 GGGGCCGGCC UCGGCCCGGA GCGG 24
(2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 3 AGGAAGGAGU CGCCGAGGA 19
(2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 4: GCAGCCUGAG GCCCCAGAGU CUGAGACGAG CC 32
(2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 5: AAACUUUUGA GAC 13
(2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 6 GUUGCCGCUG GGAGCCGGAG GC 22
(2) INFORMATION FOR SEQ ID NO: 7 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 16
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 7: CGACGCUGCC CCGCGA 16
(2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 8: AGGACUUGGG GACCCCAGAC C 21
(2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 9: GGGACGCUUG CUCCC 15
(2) INFORMATION FOR SEQ ID NO: 10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 10 CCCCUACACG GCGUCCCUCA GGCGCCCCCA UUCC 34
(2) INFORMATION FOR SEQ ID NO: 11 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21
(B) TYPE: nucleic acid
(C) STRANDEDNESS single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 11: CCUCGGGAGU CGCCGACCCG G 21
(2) INFORMATION FOR SEQ ID NO: 12 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION; SEQ ID NO: 12: UGCACGCCGC CUUCAUCCCC GGCC 24
(2) INFORMATION FOR SEQ ID NO: 13 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 13 CAUCCUAGAC CCUUUCUCCU CCAGGAGAC 29
(2) INFORMATION FOR SEQ ID NO: 14 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 14: CUCUCCGACC UGCCAC 16
(2) INFORMATION FOR SEQ ID NO: 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 15 CCUAUUCAAG ACCA 14
(2) INFORMATION FOR SEQ ID NO: 16 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 16 CCCACCUUCU GGUACCAGAU CGCGCCC 27
(2) INFORMATION FOR SEQ ID NO: 17 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 17 CGCGCCCAUC UAGGUUAUUU C 21
(2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 34
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 18: CCCCCGGUCC AAGCCUCCCC UCCACCACUG CGCC 34
(2) INFORMATION FOR SEQ ID NO: 19 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 19: AGCUUUCCCU C 11
(2) INFORMATION FOR SEQ ID NO: 20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 20: CCUCCUACCU UUUGCC 16
[2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 21 CCCCCAGCCC CUGCAGGGG 19
(2) INFORMATION FOR SEQ ID NO: 22 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 22: CUCCCCACCA CACCA 15
(2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 23: UUCGCGCUCU CGGCAGUGCC 20
(2) INFORMATION FOR SEQ ID NO: 24 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 24: GCCUCCCCCA UGCCGCCC 18 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 25 ACUAUCCACC UGCAAGACUA UCGACAUGGA G 31
[ 2 ) INFORMATION FOR SEQ ID NO: 26 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 26: AGCGCAUCGA GGCCA 15
(2) INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 27 AUCCUGUCCA AGCUGC 16
(2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 28 AGGGGGAGGU GCCGCC 16
(2) INFORMATION FOR SEQ ID NO: 29 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 29: UGCUCGCCCU GUACAACAGC A 21
(2) INFORMATION FOR SEQ ID NO: 30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 30: GAGAGUGCAG A 11
[2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 31 AGCCCGAGCC UGAGGCCGAC UACUACGCCA AGGA 34 [ 2 ) INFORMATION FOR SEQ ID NO: 32 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 32: CGCGUGCUAA U 11
(2) INFORMATION FOR SEQ ID NO: 33 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 33: CAACGAAAUC UAUGACAAGU UCAAGCAGAG UACA 34
[ 2 ) INFORMATION FOR SEQ ID NO: 34 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 34: AGAAGCGGUA CCUGAACC 18
(2) INFORMATION FOR SEQ ID NO: 35 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 (B) TYPE: nucleic acid
(C) STRANDEDNESS single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 35: GGGCAGAGCU GCGUCUGCUG AGGAGG 26
(2) INFORMATION FOR SEQ ID NO: 36 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 36 GAGGAGGCUC AAGUUAAAAG UG 22
(2) INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 37: GUACCAGAAA UACAGCAACA AUUCCUGGCG A 31
(2) INFORMATION FOR SEQ ID NO: 38 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 38 AACCGGCUGC UGGCACCCAG CGACUCGCCA GAGU 34
(2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 39: UGUGCGGCAG UGGUUGAGCC GUGGAGGGGA A 31
(2) INFORMATION FOR SEQ ID NO: 40 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 40 GGGGAAAUUG AGGGCUUUCG CCUUAGCGCC CACU 34
(2) INFORMATION FOR SEQ ID NO: 41: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 41 ACCUGGCCAC CAUUCAUGGC AUGAACC 27
(2) INFORMATION FOR SEQ ID NO: 42 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 42 AUGGCCACCC CGC 13
(2) INFORMATION FOR SEQ ID NO: 43 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 43: AGGGCCCAGC AUCUGCAAAG CUCCCGGCAC CGCC 34
(2) INFORMATION FOR SEQ ID NO: 44 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 44: CACCAACUAU UGC 13
(2) INFORMATION FOR SEQ ID NO: 45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 45: CGGCAGCUGU ACAUUG 16
(2) INFORMATION FOR SEQ ID NO: 46 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15
(B) TYPE: nucleic- acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 46: GCAAGGACCU CGGCU 15
(2) INFORMATION FOR SEQ ID NO: 47 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 47: GGAUCCACGA GCCCA 15
(2) INFORMATION FOR SEQ ID NO: 48 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 48 GCCCAAGGGC UACCAUGCCA ACUUCUGCC 29
(2) INFORMATION FOR SEQ ID NO: 49 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 49: CCUGCCCCUA CAUUUGGA 18
(2) INFORMATION FOR SEQ ID NO: 50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 50 CUGGCCCUGU ACAACCAGCA UAACCCGGG 29
(2) INFORMATION FOR SEQ ID NO: 51: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 51 GCCGUGCUGC GUGCCGCAGG CGCUGGAGCC GCU 33
(2) INFORMATION FOR SEQ ID NO: 52 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 52 UCGUGUACUA CG 12
(2) INFORMATION FOR SEQ ID NO: 53 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 53 CGCAAGCCCA AGGUGGAG 18
(2) INFORMATION FOR SEQ ID NO: 54 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 54: AGCUGUCCAA CAUGAUCGUG C 21
(2) INFORMATION FOR SEQ ID NO: 55 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 55 UGAGGUCCCG CCCCGCCCC 19 (2) INFORMATION FOR SEQ ID NO: 56: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 56: GGCUGUAUUU AAGGACACCG U 21
(2) INFORMATION FOR SEQ ID NO: 57 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 57 GACUGCGGAU CUCU 14
(2) INFORMATION FOR SEQ ID NO: 58 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 58: UUGGGCGCCU GCCUGGGGUC UCCAUCCC 28
(2) INFORMATION FOR SEQ ID NO: 59 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 59: UCCCCCACUC CCACUCCCU 19
(2) INFORMATION FOR SEQ ID NO: 60 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 60 CCUCCUGCCU GUCUGCACUA 20
(2) INFORMATION FOR SEQ ID NO: 61: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 61: UGCCCGGCAU CAAGGCAC 18
(2) INFORMATION FOR SEQ ID NO: 62 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 62: UAGUUAGAUC UAUUUAUUGA 20 (2) INFORMATION FOR SEQ ID NO: 63 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 63: UCAUUCAGUC ACCAUAGCAA CACUCUGAGA U
(2) INFORMATION FOR SEQ ID NO: 64: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 64:
GAUAACACCC AUUUUAAAGG UUGAGGAAAC AA 32
(2) INFORMATION FOR SEQ ID NO: 65: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 65:
GCCCAGAGAG GUUAAGGGA 19
(2) INFORMATION FOR SEQ ID NO: 66: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 66: CACCAGGAAC CUGCUUUAGU GGGGGAUAG 29
(2) INFORMATION FOR SEQ ID NO: 67 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 67: GGGGGAUAGU GAAGAAGACA AUAAAAGAUA GUA 33

Claims

Claims
1. An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of fibrous or connective tissue disease.
2. The enzymatic RNA molecule of claim 1, which cleaves mRNA produced from the genes encoding transforming growth factor beta (TGF-/S) , epidermal growth factor (EGF) , inhibins, activins, transforming growth factor alpha (TGF- a) , amphiregulin (AR) , bone morphogenic proteins (BMPs) , fibroblast growth factors (aFGF, bFGF) , and insulin-like growth factors (IGF-1, -2, insulin, relaxin) .
3. The enzymatic RNA molecule of claim 1, which cleaves target mRNA having a sequence selected from SEQ. ID. NOS. 1-67.
4. The enzymatic RNA molecule of claims 1, 2 or 3, wherein said RNA molecule is in a hammerhead motif.
5. The enzymatic RNA molecule of claim 4, wherein said RNA molecule is in a hairpin, hepatitis Delta virus, group 1 intron, or RNaseP RNA motif.
6. The enzymatic RNA molecule of claim 4, wherein said ribozyme comprises between 5 and 23 bases complementary to said mRNA.
7. The enzymatic RNA molecule of claim 6, wherein said ribozyme comprises between 10 and 18 bases complementary to said mRNA.
8. A mammalian cell including an enzymatic RNA molecule of claims 1, 2 or 3.
9. The cell of claim 8, wherein said cell is a human cell.
10. An expression vector including nucleic acid encoding the enzymatic RNA molecule of claims 1, 2 or 3, in a manner which allow expression of that enzymatic RNA molecule within a mammalian cell .
11. A method for treatment of a fibrous or connective tissue disease by administering to a patient an enzymatic RNA molecule of claims 1, 2 or 3.
12. The method of claim 11, wherein said patient is a human.
PCT/US1994/006331 1993-06-09 1994-06-02 Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease WO1994029452A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU70538/94A AU7053894A (en) 1993-06-09 1994-06-02 Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7434393A 1993-06-09 1993-06-09
US08/074,343 1993-06-09

Publications (2)

Publication Number Publication Date
WO1994029452A2 true WO1994029452A2 (en) 1994-12-22
WO1994029452A3 WO1994029452A3 (en) 1995-02-02

Family

ID=22119047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/006331 WO1994029452A2 (en) 1993-06-09 1994-06-02 Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease

Country Status (2)

Country Link
AU (1) AU7053894A (en)
WO (1) WO1994029452A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146886A (en) * 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US6436909B1 (en) * 1999-09-17 2002-08-20 Isis Pharmaceuticals, Inc. Antisense inhibition of transforming growth factor-β expression
EP1326627A1 (en) * 2000-10-04 2003-07-16 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists
US7125660B2 (en) 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
US7833526B2 (en) 2000-10-04 2010-11-16 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists
US8629117B2 (en) 1998-06-10 2014-01-14 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh Method for stimulating the immune system
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006693A1 (en) * 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
WO1992017206A1 (en) * 1991-03-28 1992-10-15 The Victoria University Of Manchester Wound healing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006693A1 (en) * 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
WO1992017206A1 (en) * 1991-03-28 1992-10-15 The Victoria University Of Manchester Wound healing

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PROC.NATL.ACAD.SCI. vol. 89 , August 1992 pages 7305 - 7309 WOOLF, T.M. ET AL. 'Specificity of antisense oligonucleotides' *
THE EMBO JOURNAL vol. 8, no. 12 , 1989 pages 3685 - 3691 BECKER, D. ET AL. 'Proliferation o human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor' *
Z.GASTROENTEROL. (SUPPL. 1) vol. 30 , 1992 pages 5 - 16 GRESSNER, A.M. 'Hepatic fibrogenesis: The puzzle of interacting cells, fibrogenic cytokines, regulatory loops, and extracellular matrix molecules' *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146886A (en) * 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US6852535B1 (en) 1994-08-19 2005-02-08 Sirna Therapeutics, Inc. Polymerase III-based expression of therapeutic RNAS
US8629117B2 (en) 1998-06-10 2014-01-14 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh Method for stimulating the immune system
US6436909B1 (en) * 1999-09-17 2002-08-20 Isis Pharmaceuticals, Inc. Antisense inhibition of transforming growth factor-β expression
EP1296643A1 (en) * 1999-09-17 2003-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of transforming growth factor-beta expression
EP1296643A4 (en) * 1999-09-17 2005-07-27 Isis Pharmaceuticals Inc Antisense modulation of transforming growth factor-beta expression
US7125660B2 (en) 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
EP1326627A1 (en) * 2000-10-04 2003-07-16 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists
US7833526B2 (en) 2000-10-04 2010-11-16 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists
US8119136B2 (en) 2000-10-04 2012-02-21 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists
EP1326627A4 (en) * 2000-10-04 2004-06-16 Molecular Medicine Res Inst Methods of modulating apoptosis by administration of relaxin agonists or antagonists
US9534034B2 (en) 2000-10-04 2017-01-03 Molecular Medicine Research Institute Methods of modulating apoptosis by administration of relaxin agonists or antagonists
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
US9963703B2 (en) 2016-02-09 2018-05-08 Autotelic Llc Compositions and methods for treating pancreatic cancer

Also Published As

Publication number Publication date
WO1994029452A3 (en) 1995-02-02
AU7053894A (en) 1995-01-03

Similar Documents

Publication Publication Date Title
US5989906A (en) Method and reagent for inhibiting P-glycoprotein (mdr-1-gene)
EP0786522A2 (en) Enzymatic RNA molecules for treatment of stenotic conditions
US5750390A (en) Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
US6017756A (en) Method and reagent for inhibiting hepatitis B virus replication
US5795778A (en) Method and reagent for inhibiting herpes simplex virus replication
EP0725788B1 (en) 2'-amido and 2'-peptido modified oligonucleotides
AU687001B2 (en) Method and reagent for inhibiting cancer development
EP0748382B1 (en) Non-nucleotide containing enzymatic nucleic acid
US5610054A (en) Enzymatic RNA molecule targeted against Hepatitis C virus
US5693535A (en) HIV targeted ribozymes
US5972699A (en) Method and reagent for inhibiting herpes simplex virus replication
US5616490A (en) Ribozymes targeted to TNF-α RNA
EP0728205B1 (en) Reagent for treatment of arthritic conditions
WO1995004818A1 (en) Method and reagent for inhibiting human immunodeficiency virus replication
US5599704A (en) ErbB2/neu targeted ribozymes
US5610052A (en) Enzymatic RNA with activity to ras
US5639655A (en) PML-RARA targeted ribozymes
US5622854A (en) Method and reagent for inhibiting T-cell leukemia virus replication
US6258585B1 (en) Method and reagent for inhibiting influenza virus replication
WO1994029452A2 (en) Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease
US6544755B1 (en) Method and reagent for treatment of diseases by expression of the c-Myc gene
US6492512B1 (en) Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression
AU730506B2 (en) Method and reagent for inhibiting cancer development
AU5661700A (en) Method and reagent for treatment of animal diseases
CA2168566A1 (en) Method and reagent for inhibiting human immunodeficiency virus replication

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA